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The cardiometabolic disease is a cluster of diseases and conditions, including 
cardiovascular and metabolic diseases such as coronary heart disease, stroke, type 2 diabetes, 
and non-alcoholic fatty liver disease. The high morbidity and mortality of cardiometabolic 
disease has made it become a major public health problem worldwide. Cardiovascular diseases 
contribute to almost one-third of all global deaths 1. In addition, type 2 diabetes is a leading 
cause of blindness, kidney failure, and lower limb amputation, which deprives more than 400 
million people of their healthy life expectancy 2. Thanks to the efforts by researchers in the past 
decade, we can witness significant strides in identifying the risk factors and potential 
mechanisms as well as effective prevention and treatment 2-5. However, much still needs to be 
done. More recently, accumulative evidences have suggested a potential role of microvascular 
(dys)function and physical (in)activity in cardiometabolic diseases. This dissertation will further 
focus on this topic. In the present chapter, we will mainly introduce the definition and 
assessment of microvascular (dys)function and physical (in)activity, as well as their potential 
role in cardiometabolic diseases based on previous findings. 
 
The microcirculation 
Definition and function 
Based on anatomical criteria, the microcirculation consists of blood vessels with a 
diameter<150 μm, including arterioles, capillaries, venules, and some specialized structures 
such as arteriovenous shunts 6,7. Alternatively, all the vessels that have myogenic response to 
an increasing pressure, such as the smallest arteries, can be included. Small arteries and 
arterioles are characterized by abundant vascular smooth muscle cells encircling the 
endothelium, which is essential for the high resistance at the arteriole level. Capillaries are the 
smallest vessels and compose of a layer of endothelial cells surrounded by the basement 
membrane. With different structures (continuous, fenestrated, and discontinuous), the 
permeability of capillaries differs across the body and allows substance exchange between 
capillaries and tissue via diffusion, vesicles, intracellular clefts, and fenestration. Venules are 
capable of constriction despite the weaker muscular coat, and play a role in regulating 
hydrostatic pressure in capillaries. Attributed to the porous structure, fluid and macromolecular 
exchange can also occur at the venule level. The coordinated collaboration of different vessels 
and cells is the basis of microvascular function. 
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The microcirculation plays a variety of roles in both physiological and pathophysiological 
states. A primary function of the microcirculation is delivering oxygen and nutrients to and 
removing the waste from the tissue 8. By affecting flowmotion and hydrostatic pressure at the 
capillary level, the microcirculation optimizes the delivery according to local metabolic demand. 
Remarkably, it can maintain a relatively stable hydrostatic pressure and thus a constant 
substance exchange with tissue, regardless of large fluctuations in upstream blood pressure 9. 
This ability to create a resistance to flow also enables the microcirculation to be a determinant 
of blood pressure. Constriction of arterioles, metarterioles, and precapillary sphincters keeps 
more blood in the artery and increases systemic blood pressure, whereas dilatation of these 
resistance vessels decreases peripheral resistance and systemic blood pressure. In addition to 
regulating substance exchange and blood pressure, the microcirculation also contributes to 
heat change between skin surface and thermal environment, protection of the brain 
environment by the blood-brain barrier, assistance in endocrine system communication, and 
immune response 8-11. 
 
 
Figure 1.1 Water system on the earth as a metaphor for microcirculation. The microcirculation can be 
compared to the water system on the earth. It provides nutrition to the land, transmits information across regions, 
and forms a variety of terrains and cultures. The figure shows part of Shanghai area (map data are available on 
Amap.com). Blue: land; Red: water; Green: green belt; Light blue: scenic area 
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Microvascular measurements 
Since M. Malpighi and A. van Leeuwenhoek first observed the blood flow through capillaries 
under the microscope hundreds of years ago, quantitative techniques have been developed to 
measure microvascular parameters 7. For example, videomicroscopy can dynamically visualize 
the microcirculation; laser Doppler flowmetry can quantify blood flow in the microcirculation; 
magnetic resonance imaging (MRI) can identify cerebral small vessel diseases. Besides 
measurements in the resting state, we can measure stimulus-induced responses to determine 
(maximal or submaximal) microvascular reactivity, such as local heating for the skin and flicker 
light for the retina 12,13. What’s more, technical advances have allowed a transition of some 
measurements from manual/semi-automated to fully automated image analysis, which enables 
application in population-based studies. Recent studies are gradually applying these 
techniques to observe the structure and function of the microcirculation in (patho)physiological 
status. The use of these techniques may provide further insight into the status of the 
microcirculation in the pathogenesis of various diseases, and show the similarity and 
heterogeneity across territories. However, the different protocols of some novel techniques may 
cause inconsistent results across studies, and are yet to be standardized. Therefore, the 
description of measurement protocols is necessary. 
 
Microvascular dysfunction is a systemic phenomenon 
Microvascular dysfunction and type 2 diabetes 
Microvascular complications of type 2 diabetes typically include retinopathy, nephropathy, and 
neuropathy. Beckman et al. advanced the notion that microvascular dysfunction may be a 
widespread phenomenon rather than only affecting one part of the body 14. Indeed, we and 
others have found that type 2 diabetes and hyperglycemia are associated with microvascular 
dysfunction in different territories in the body, including wider retinal arterioles 15-21, impaired 
flicker light-induced retinal arteriolar dilation 22, impaired heat-induced skin hyperemic response 
22, and cerebral small vessel disease 23. The mechanism by which hyperglycemia impairs 
microvascular function is not well elucidated. It may involve mitochondrial overproduction of 
reactive oxygen species 24,25, the formation of advanced glycation end products (AGEs) 26, 
increased polyol pathway and hexosamine pathway 24, 26, 27, and activation of protein kinase C 
isoforms 24. Notably, microvascular dysfunction can occur before the diagnosis of type 2 
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diabetes and even prediabetes 22,23,28-30, suggesting hyperglycemia is not a necessary cause 
of microvascular dysfunction. A broad array of cardiometabolic risk factors such as age 31, male 
sex 31, obesity 32, hypertension 33, physical inactivity 34,35, and current smoking 31 may also be 
independent determinants of microvascular dysfunction. 
Conversely, microvascular dysfunction may also contribute to type 2 diabetes. An 
extensive number of studies have shown that microvascular dysfunction, as measured by 
different techniques, is associated with a higher risk of type 2 diabetes 28-30. This association 
may be explained by impaired insulin-mediated glucose disposal and, possibly, insulin 
secretion 36. Insulin can induce endothelial-dependent vasodilation and functional capillary 
recruitment, thus promoting muscle glucose uptake in human and animals 36-41. In rats, 
inhibition of nitric oxide synthase, which completely blocked the effect of insulin on both blood 
flow and capillary recruitment, can blunt insulin-mediate glucose uptake by approximately 40% 
41. More recently, evidences suggest that insulin with physiological concentration has a more 
significant impact on capillary recruitment than on blood flow 40. In addition, microvascular 
dysfunction around pancreatic islets may contribute to a decreased insulin secretion with or 
without beta cell dysfunction, though there is no established causal link in humans yet 42,43. 
Taken together, the relationship between microvascular dysfunction and type 2 diabetes 
may be bidirectional, which forms a vicious circle and promotes the development of type 2 
diabetes. Until now, glucose-lowering treatment can reduce the risk of microvascular 
complications in diabetes and prediabetes 44-47, whereas there is lacking evidence to show 
preventive or treatment effect of the medication that improves microvascular function on 
diabetes 48. 
Islet microvascular dysfunction: a potential target to modulate beta cell function 
The pancreatic islet is characterized by a rich vascularization 49. Intraislet endothelial cells are 
thin, highly fenestrated, and closely interacted with beta cells, allowing for rapid detection of 
glucose levels and dissemination of secreted insulin 49. Pericytes, which cover the endothelial 
cells, play a role in maintaining structural stability and controlling vascular permeability and 
blood flow 50,51. The bidirectional communication between beta cells and microvascular cells is 
essential for beta cell survival, proliferation, and insulin secretion 49,50. 
   Mouse experiments have provided shreds of evidence showing that microvascular 
dysfunction may lead to impaired insulin secretion. Islet microvascular endothelial cells play a 
critical role in islet development and beta cell proliferation by producing vasoactive/angiogenic 
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substances and growth factors 42,52,53. In the adult pancreas, on the one hand, microvascular 
dysfunction such as hypovascularization and endothelial dysfunction can reduce blood flow, 
resulting in insufficient delivery of oxygen and nutrients as well as decreased insulin 
secretagogues entry into the beta cells and insulin’s entry into the circulation 43,54. On the other, 
hypervascularization may promote islet inflammation and beta cell death in the long term 54. 
It remains dubious whether the present findings, mainly on rodent islets, apply to human 
islets. Although humans have a similar range of islet sizes as rodents 55, the cellular 
arrangement and microvascular morphology differ between human and rodent islets. Unlike 
rodent islets that classically comprise a beta cell core (60-80% of cells in islets) surrounded by 
a non-beta-cell mantle, human islets are proposed to have a trilaminar structure in which beta 
cells (50-75%) directly contact with non-beta cells on both sides 56-58. The human islets also 
have less dense and tortuous with thicker basement membrane than rodent islets 59-61. The 
islets from a mouse model for obese type 2 diabetes are characterized by capillary loss 62, 
whereas the islets from humans with type 2 diabetes exhibit increased capillary density and 
fragmented capillaries 59. These findings suggest that there may be a different relationship 
between islet microcirculation and endocrine cells in humans versus rodents. Therefore, the 
association of microvascular dysfunction of beta cell function needs to be further evaluated in 
humans. 
Microvascular dysfunction and cardiovascular risk 
Micro- and macrovascular diseases often coexist in patients with long-term pathological states. 
One explanation can be shared risk factors and mechanisms 63. We and others have found that 
multiple cardiovascular risk factors are associated with microvascular dysfunction and disease, 
including older age, male sex, smoking, hyperglycemia, hypertension, inflammation, and 
dyslipidemia 31,63. The risk factors impair micro- and macro-vasculatures via various 
mechanisms. Aging, for example, exacerbates oxidative stress and leads to exhaustion of 
vascular progenitor cells 64; adult men have less distensible arteries than women, and female 
sex hormones protect against vascular damage 65,66. These cardiovascular risk factors and 
corresponding pathological pathways impair vasculatures across the body and are frequently 
present in combination, thereby magnifying the potential for vascular damage 63. 
The other explanation is that micro- and macrovascular dysfunction may be interconnected. 
Microvascular diseases such as retinopathy and nephropathy are independently associated 
with incident cardiovascular disease 63,67. Although the underlying mechanism remains unclear, 
microvascular dysfunction may play a potential role in the development of cardiovascular 
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disease. As a determinant of peripheral vascular resistance, it may increase blood pressure 
and impair the endothelial cells of arteries. As a channel of delivering oxygen and nutrients, it 
can also result in tissue ischemia and hemorrhage. Besides, inflammatory mediators generated 
in the microvasculature may further activate an inflammatory response in lesion-prone micro- 
and macrovasculatures, which initiates the development of an atherosclerotic plaque 68. These 
mediators build a link of micro- and macrovascular status between non-culprit and culprit 
territories 69-72. As macrovascular lesions may also affect microvascular function 63, the 
interrelated micro- and macro-vascular dysfunction, along with presence of risk factors, may 
constitute a vicious circle of tissue damage. 
 
Physical activity and cardiovascular disease 
Physical activity, inactivity, and sedentary behavior 
With increasing evidence indicating influences of physical activity and sedentary behavior on 
health outcomes, many countries and organizations have published relevant guidelines. Both 
the World Health Organization (WHO) and the United States guidelines for physical activity 
suggest a combination of moderate to vigorous-intensity aerobic physical activity and muscle-
strengthening activities 73,74. The guidelines also suggest reducing sitting time. According to the 
definitions by WHO 73,75, moderate-intensity physical activity consumes approximately 3-6 
metabolic equivalents (MET, the ratio of a person's working metabolic rate relative to their 
resting metabolic rate), and vigorous-intensity consumes more than 6 METs. Physical inactivity 
is defined as an absence or sufficient level of physical activity required to meet the current 
physical activity recommendations (less than 150 minutes of moderate-intensity activity per 
week for adults). Sedentary behavior is defined as any waking behavior characterized by an 
energy expenditure less than 1.5 METs, generally referring to sitting, reclining, and lying 
posture. 
For decades, assessment of physical activity has been totally based on questionnaires. 
Despite the advantages of convenience and time-saving, use of questionnaires has certain 
limits of validity due to recall and social desirability bias 76. Recently, the development of 
objective monitors has enabled off-laboratory assessment of physical activity and more precise 
and extended data, such as volume and pattern of activity over multiple days 77. By use of such 
devices, previous study found that moderate to vigorous-intensity physical activity and 
sedentary behavior is mainly accumulated in sporadic bouts (i.e., bouts of <10 min) in youth 77. 
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These portions may be less memorable and therefore underestimated by self-reported 
questionnaires. Additionally, levels of light-intensity physical activity can hardly be assessed via 
questionnaires. The ignored portions of physical activity and sedentary behavior may also raise 
health benefits or risks. 
Association of physical activity and sedentary behavior with cardiovascular risk 
Based on self-reported physical activity and sedentary behavior, an extensive amount of 
evidence has supported an inverse relationship between physical activity and cardiovascular 
risk 78. Notably, physical activity may have a dose-response effect on the risk of cardiovascular 
disease. Compared with individuals having low amounts of physical activity, those with 
moderate and high amounts had 20% and 40% reduced cardiovascular risk, respectively 78. 
Nevertheless, higher levels of physical activity are not able to offset the increased risk of 
cardiovascular disease associated with being overweight or obese, whereas high levels of 
physical fitness can 78,79. This finding suggests that physical activity may not certainly lead to 
physical fitness. It may also reflect less precise assessment of physical activity by self-reported 
questionnaires than assessment of physical fitness. Therefore, further studies of physical 
activity measured by objective monitors are needed for public health recommendations. 
    Sedentary behavior may be a risk factor for cardiovascular disease, independently of 
physical activity. It is possible that an individual having high levels of physical activity sits more 
of the rest of the day, and therefore has a lower energy expenditure. Indeed, among physically 
active individuals, those spending more time sitting have an increased risk of all-cause and 
cardiovascular mortality compared with those sitting less 80. However, it may be unhealthy 
behavior such as snacking while watching TV, but not the sedentary behavior per se, that 
accounts for the adverse associations. Besides the volume of sedentary behavior, the pattern 
also matters. Epidemiological evidence suggests that prolonged sedentary bouts are 
associated with worse cardiometabolic risk factors and higher risks of cardiovascular disease 
81,82. What’s more, experimental trials have found that interrupting bouts of sedentary behavior 
with light-intensity activity can significantly benefit the cardiometabolic health, which was 
independent of total sedentary time 79. 
 
Objectives and outline of this dissertation 
Taken together, both microvascular dysfunction and physical (in)activity may prove important 
for cardiometabolic disease. Microvascular dysfunction may be present long before the 
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diagnosis of type 2 diabetes and associated with altered beta cell function. In addition, both 
microvascular dysfunction and physical inactivity may contribute to the development of 
cardiovascular disease. Testing these hypotheses reduces the knowledge gap in the etiology 
of cardiometabolic diseases, which is essential for prevention and treatment. However, current 
knowledge is limited by either technique for microvascular and physical activity assessments in 
humans or insufficient adjustment for confounding. Therefore, the general objectives of this 
dissertation were to investigate the associations of microvascular dysfunction and physical 
activity with cardiometabolic health, in a population-based cohort study (The Maastricht Study), 
with a broad array of potential confounders taken into account. Figure 1.2 demonstrates a 
schematic overview of the studies included in this dissertation.  
In Chapter 2, we described detailed protocols of a variety of non-invasive microvascular 
measurements in skin, retina, brain, and sublingual tissue as well as plasma and urine 
biomarker assessments, which have been implemented in The Maastricht Study. We 
additionally provided a summary of the main findings and perspectives of microvascular 
phenotyping, with an update up to 2018. 
In Chapter 3, we investigated the associations of oral glucose tolerance test-based 
glucose metabolism status (normal glucose metabolism, prediabetes, type 2 diabetes) and 
measures of blood glucose with retinal microvascular diameters. In addition, we explored 
whether retinal arteriolar and venular diameters were mutually related. 
In Chapter 4, we explored whether islet microvascular dysfunction, using measures of 
generalized microvascular function, was associated with fasting insulin secretion and glucose-
stimulated insulin secretion. 
In Chapter 5, we performed a systematic evaluation of the association of microvascular 
dysfunction with incident cardiovascular disease. We also explored whether the association 
differs regarding cardiovascular disease in different vascular beds (coronary, cerebral, and 
peripheral). 
In Chapter 6, we investigated the association between the volume and the pattern of 
physical activity and sedentary behavior with incident cardiovascular disease. 
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Figure 1.2 Schematic overview of the studies included in this dissertation. Solid arrows indicate associations 
that we hypothesized and investigated in the present dissertation. Dashed lines represent potential reverse 
associations. 
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Abstract 
Microvascular dysfunction (MVD) is a common pathophysiological change in various diseases, 
such as type 2 diabetes mellitus (T2DM), heart failure, dementia and depression. Recent 
technical advances enable the measurement and quantification of microvascular changes 
non-invasively in humans. In this paper, we describe the protocols of the microvascular 
measurements applied in The Maastricht Study, an ongoing prospective population-based 
cohort study, which includes a variety of non-invasive measurements in skin, retina, brain, and 
sublingual tissue as well as plasma and urine biomarker assessments. Following this, we 
summarize our main findings involving these microvascular measurements up to 2018. Finally, 
we provide a brief perspective of future microvascular investigations, within the framework of 
The Maastricht Study 
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Introduction 
Microvascular dysfunction (MVD) is involved in the development and progression of various 
diseases, such as type 2 diabetes mellitus (T2DM), heart failure, dementia, and depression 1-8. 
The microcirculation performs essential functions in both physiological and pathophysiological 
states, including delivery of oxygen and nutrients, removal of waste, heat exchange with the 
environment, assistance in endocrine system communication, blood pressure regulation, and 
immune response 9-12. Investigation of microvascular function can thus expand our knowledge 
of the pathophysiology of different diseases. 
Nowadays, state-of-the-art technologies enable assessment of both structural and 
functional aspects of the human microcirculation in different regions 13–21. Introducing these 
measurements in a population-based setting permits the study of microvascular changes that 
occur in various diseases, as well as their similarities and differences across various territories. 
Additionally, the description of measurement protocols is necessary in order to identify whether 
differences in results across studies are based on differences in methodology. 
The general design of The Maastricht Study, a population-based cohort study, has been 
described previously 22. In the present paper, we describe a wide range of microvascular 
measurements that have been implemented gradually in The Maastricht Study and provide a 
summary of the main findings and perspectives on microvascular phenotyping, with an update 
through the end of 2018. 
 
Methods 
A detailed description of the study population and design of The Maastricht Study can be found 
in the Supplemental Material and a previous paper 22. The Maastricht Study is an ongoing 
observational, prospective, population-based cohort study. All residents of the southern part of 
the Netherlands aged 40–75 years are eligible for participation. Baseline data assessment 
took place from November 2010 to January 2020. Table 2.1 gives an overview of all 
microvascular measurements and corresponding variables used to assess microvascular 
(dys)function that have been implemented in The Maastricht Study. Microvascular 
measurements applied from the onset of the study include skin capillary density and 
recruitment, skin flowmotion, and biomarkers of endothelial function obtained from plasma and 
urine samples. Measurements of heat-induced skin hyperemic response, retinal static and 
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dynamic measurements, and magnetic resonance imaging (MRI) measurements were 
introduced after approximately 8, 11, and 13 months, respectively. Lastly, measurement of 
endothelial glycocalyx thickness was introduced 22 months after initiation of the study. Data 
collection in The Maastricht Study and validation of the microvascular measurements are 
described in the Supplemental Material. 
Retinal microvascular reactivity 
The retinal microvascular dilation response to flicker light, which is related to nutritive demands 
of activated retinal neurons and is nitric-oxide-dependent 16,23, is measured in a dimly lit room 
using the Dynamic Vessel Analyzer (Imedos Systems GmbH, Jena, Germany). Mydriasis is 
induced with 2 drops of tropicamide (0.5%) and 1 drop of phenylephrine (2.5%) 15 minutes prior 
to the Dynamic Vessel Analyzer measurements. For safety reasons, participants with an 
intraocular pressure exceeding 30 mm Hg are excluded from retinal measurements. Per 
participant, we randomly measure the left or right eye. During the measurement, the participant 
is instructed to focus on the tip of a fixed needle inside the retinal camera (FF450; Carl Zeiss 
AG, Jena, Germany) while the fundus of the eye is examined under green measuring light 
(530-600 nm; illumination of fundus approximately 6,500 lux). Straight arteriolar and venular 
segments of approximately 1.5 mm in length located 0.5-2.0 disc diameters from the margin of 
the optic disc in the temporal section are examined (Figure 2.1A, left panel, zone “b”).  
After the specific vessel profile is recognized, its diameter is automatically and 
continuously measured for 150 seconds. A baseline recording of 50 seconds is followed by a 
40-second flicker light exposure period (flicker frequency 12.5 Hz 24, bright:dark contrast ratio 
25:1) and a subsequent 60-second recovery period (Figure 2.1A, right panel). We use a 
40-second flicker light stimulation based on the findings of Nagel et al. 25 and Kotliar et al. 26, 
who observed that healthy individuals exhibited maximum dilation immediately after the 
20-second flicker stimulation, whereas the time to maximal arteriolar dilation of obese 
individuals was prolonged. We have chosen to perform a single cycle of 40-second flicker light 
stimulation because of time restraints for the large amount of measurements in The Maastricht 
Study. Notably, despite a difference in flicker duration, the average arteriolar/venular 
percent-dilation responses we observe are comparable to those in studies using 3 cycles of 
short flicker light stimulation. The Dynamic Vessel Analyzer automatically corrects for 
alterations in luminance caused by, for example, slight eye movements. During blinks and small 
eye movements, the registration stops, and it restarts once the vessel segments are 
automatically reidentified 16. 
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The integrated Dynamic Vessel Analyzer software (version 4.51; Imedos Systems) 
automatically calculates baseline diameter and percentage dilation. Baseline diameter is 
calculated as the average diameter size of the 20- to 50-second recording and is expressed in 
measurement units, where 1 measurement unit is equal to 1 μm of the Gullstrand eye 27. 
Percentage dilation over baseline is based on the average dilation achieved at the time points 
10 seconds and 40 seconds during the flicker stimulation period. Two regression lines are 
drawn (at intervals of 0-<10 seconds and 10-40 seconds during flicker stimulation), and results 
are averaged to assess average percentage of dilation. The purpose of taking the average 
dilation is to account for interindividual variation in the curve shape during dilation. 
Retinal microvascular diameters and morphology 
State-of-the-art technology enables quantification and analysis of various features of retinal 
microvasculature (semi)automatically (e.g., vascular diameters, tortuosity, fractal dimension, 
and bifurcation features (Figure 2.1A, left panel). In The Maastricht Study, fundus photography 
of both eyes is performed 15 minutes after the pupils have been dilated with tropicamide 0.5% 
and phenylephrine 2.5%. All fundus photographs are made with a focus, shot, and tracker 
fundus camera (model AFC-230; Nidek Co. Ltd., Aichi, Japan) in 45 degrees of at least 3 fields: 
1 field centered on the optic disc, 1 field centered on the macula, and 1 temporal field positioned 
1 disc diameter from the center of the macula.  
Static retinal vessel analysis is performed with the RHINO software developed by the 
RetinaCheck Project group at the Eindhoven University of Technology (Eindhoven, the 
Netherlands) 17,18. Retinal vessel diameters are measured 0.5-1.0 disc diameter away from the 
optic disc margin and 1.0-1.5 disc diameter away from the fovea (macula) center (zone “a”), 
while retinal vascular tortuosity, retinal fractal dimension, and bifurcation-based features are 
studied within 1.0-2.5 disc diameters (zone “b”) and 1.0-3.0 disc diameters (zone “c”) from 
the optic disc center or fovea (macula) center, respectively (Figure 2.1A, left panel). The scale 
factor is based on the optic disc diameter, which is assumed to be 1,800 μm 28. 
Retinal vessel diameters are presented as central retinal arteriolar equivalent and central 
retinal venular equivalent. Central retinal arteriolar equivalent and central retinal venular 
equivalent represent the equivalent single-vessel parent diameters for the 6 largest arterioles  
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Figure 2.1 Noninvasive microvascular measurements in The Maastricht Study, Maastricht, the 
Netherlands, 2010–2018. A) Retinal microvascular diameters and morphology and retinal microvascular 
reactivity. Left: a typical example of an optic disc-centered image showing the retinal microvasculature. Zones a, b, 
and c are defined as the regions 1.0–1.5, 1.0–2.5, and 1.0–3.0 disc diameters away from the optic disc center or 
fovea (macula) center, respectively. Right: schematic registration of a 40-second flicker light-induced retinal 
arteriolar dilation response using the Dynamic Vessel Analyzer (Imedos Systems GmbH, Jena, Germany). B) Skin 
capillary density and recruitment. Left: skin capillaries are visualized in the dorsal skin of the distal phalanges of the 
third and fourth fingers of the right hand by means of a digital video microscope. Right: a typical example of skin 
capillaries. C) Skin microvascular flowmotion (SMF) and skin heating response. Upper left panel: SMF 
measurement is performed by use of a laser Doppler system equipped with 2 probes at the dorsal side of both the 
left wrist and the left ankle. Upper right panel: frequency spectrum of SMF between 0.01 Hz and 1.60 Hz, divided 
into 5 SMF components based on the cutpoints of Stefanovska et al. 15: endothelial, 0.01-0.02 Hz; neurogenic, 
0.02-0.06 Hz; myogenic, 0.06-0.15 Hz; respiratory, 0.15-0.40 Hz; and cardiac, 0.40–1.60 Hz. Lower panel: 
schematic registration of a 23-minute heat-induced skin hyperemic response using laser Doppler flowmetry. D) 
Magnetic resonance imaging markers of cerebral small-vessel disease. Upper left panel: T1-weighted scan. Upper 
right panel: T1-weighted image with segmented volumes overlaid. Lower left panel: T2-weighted fluid-attenuated 
inversion recovery (FLAIR) scan. Lower right panel: T2-weighted FLAIR image with white matter hyperintensities 
marked in red. E) Endothelial glycocalyx thickness. Left: sublingual microcirculation is visualized by means of a 
sidestream dark field camera. Right: a typical example of sublingual microcirculation displayed by 
videomicroscopy. F) Plasma biomarkers. Venous plasma samples are taken to measure biomarkers of endothelial 
function. G) Urine biomarkers. Urinary albumin concentration is measured by means of two 24-hour urine 
collections. Albuminuria is defined as albumin excretion≥30 mg/24 hours. 
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and largest venules in the region of interest, respectively. The calculations are based on the 
improved Knudtson-Hubbard formula 29. 
Retinal microvascular morphology includes retinal microvascular tortuosity, fractal 
dimension, and bifurcation-based features. We measure retinal arteriolar and venular tortuosity 
using both conventional and exponential methods 30. We calculate fractal dimension on the 
basis of the box-counting method 31. Calculation of microvascular bifurcation-based features, 
including branching angles, bifurcation index, asymmetry ratio, area ratio, and junction 
exponent, has been described elsewhere 32. 
Skin capillary density and recruitment 
Skin microcirculation is considered a representative vascular bed with which to examine 
generalized systemic MVD 33. In The Maastricht Study, skin capillaries are visualized in the 
dorsal skin of the distal phalanges of the third and fourth fingers of the right hand using a digital 
video microscope (CapiScope; KK Technology, Honiton, United Kingdom) with a system 
magnification of×100 13. Participants are studied in the supine position with the investigated 
hand placed at heart level. The finger is fixed on a finger holder, and a miniature cuff (digit cuff; 
D. E. Hokanson, Inc., Bellevue, Washington) is applied to the base of the investigated finger 
(Figure 2.1B, left panel). Capillaries are visualized 4.5 mm proximal to the terminal row of 
capillaries in the middle of the nailfold, where capillaries run perpendicularly to the skin (Figure 
2.1B, right panel). The investigator selects a region of interest of 1 mm2 of skin area. 
Capillary density (mean of 2 fields) is measured under 3 conditions. First, baseline capillary 
density, defined as the number of continuously erythrocyte-perfused capillaries per 1 mm2 of 
skin, is measured. Capillaries are counted for 15 seconds at baseline. Second, capillary 
recruitment during postocclusive peak reactive hyperemia is assessed after arterial occlusion. 
Arterial occlusion is applied using a miniature cuff at the base of the investigated finger inflated 
to suprasystolic pressure (260 mmHg) for 4 minutes. Immediately following release of the cuff, 
all (continuously and intermittently) perfused capillaries are counted for 15 seconds. Third, 
venous congestion is applied, with the cuff inflated to 60 mmHg for 2 minutes, and all 
(continuously and intermittently) perfused capillaries are counted for 15 seconds in the second 
minute. The number of perfused capillaries is counted in the recorded digital raw data using a 
custom-built semi-automatic image analysis application (CapiAna) constructed by 2 of the 
authors (E.H.B.M.G. and A.J.H.M.H.) 13. For analysis, we use absolute numbers of capillaries 
recorded at baseline, after arterial occlusion, and during venous congestion. In addition, we 
calculate percentage of capillary recruitment following arterial occlusion ([(capillary density 
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during hyperemia-baseline capillary density)/baseline capillary density]×100) and percentage 
of capillary density during venous congestion ([(capillary density during venous 
congestion-baseline capillary density)/baseline capillary density]×100). 
Skin flowmotion 
Flowmotion is the fluctuation of microvascular perfusion as a result of spontaneous oscillations 
in arteriolar diameter (i.e., vasomotion). Skin microvascular flowmotion (SMF) can be 
monitored by laser Doppler flowmetry. This technique is based on a fiber-optic probe emitting 
laser light (wavelength 780 nm) to the target tissue and collecting the back-scattered light, 
which undergoes a shift in frequency proportional to the velocity of moving erythrocytes. The 
measuring depth is 0.5-1.0 mm, and the signal is predominantly derived from arterioles and 
venules 16. We perform SMF measurements using a laser Doppler system (PeriFlux 5000; 
Perimed AB, Järfälla, Sweden) equipped with 2 probes, one at the dorsal side of the left wrist 
and the other at the dorsal side of the left ankle (Figure 2.1C, upper left panel). Since 
flowmotion has predominantly been observed in participants with a skin temperature above 
29.3℃ 34, the laser Doppler probes are maintained at 30℃. The laser Doppler flowmetry output 
is recorded for 25 minutes with a sample rate of 32 Hz, which gives semi-quantitative 
assessment of skin blood flow expressed in arbitrary perfusion units 35. 
A fast-Fourier transform algorithm is performed by means of a custom-built automatic 
software application created in MATLAB (MathWorks, Inc., Natick, Massachusetts) to 
distinguish the contributions of different frequency domains to the signal. The frequency 
spectrum between 0.01 Hz and 1.60 Hz is divided into 5 SMF components (using the cutpoints 
of Stefanovska et al. 15): endothelial, 0.01-0.02 Hz; neurogenic, 0.02-0.06 Hz; myogenic, 
0.06-0.15 Hz; respiratory, 0.15-0.40 Hz; and cardiac, 0.40-1.60 Hz (Figure 2.1C, upper right 
panel). The results are presented as power spectrum density, which describes the density of 
power in a stationary, random process per unit of frequency and can be expressed as 
(perfusion units)2 per Hz. Total energy is obtained by the sum of the power density values of the 
total frequency spectrum. To correct for spatial and temporal variations in the laser Doppler 
flowmetry signal, the relative contributions of the components are calculated by dividing the 
power of each component by the power of the total SMF (0.01–1.60 Hz) 36. 
Skin heating response 
Local heat induces skin hyperemia and increases the skin blood flow. This heat-induced skin 
response is mainly dependent on nitric oxide and endothelium-derived hyperpolarizing factors 
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37. To quantify this response, skin blood flow is measured by means of a laser Doppler system 
(PeriFlux 5000) as described above (Figure 2.1C, upper left panel). Two thermostatic probes 
are attached to the wrist and ankle to induce local heating. Skin blood flow is first recorded 
unheated for 2 minutes to serve as a baseline measure. Next, the temperature of the probe is 
rapidly and locally increased to 44℃ and is then kept constant for the next 23 minutes (Figure 
2.1C, lower panel). The heat-induced skin hyperemic response is expressed as the percentage 
increase in average perfusion units during the 23-minute heating phase over the average 
baseline perfusion units. 
MRI markers of cerebral small-vessel disease 
Brain MVD is reflected by MRI features of cerebral small-vessel disease, including white matter 
hyperintensities (WMHs), lacunar infarcts, and cerebral microbleeds. In The Maastricht Study, 
MRI is performed on a 3T MRI scanner (Siemens Magnetom Prisma-Fit Syngo MR D13D; 
Siemens AG, Erlangen, Germany) using a 64-element head coil for parallel imaging (Figure 
2.1D). The MRI protocol consists of a 3-dimensional T1-weighted sequence (repetition time 
[TR]/echo time [TE]/inversion time [TI] 2,300 ms/2.98 ms/900 ms, 1.00-mm cubic voxel, 176 
continuous slices, matrix size of 240×250, and reconstructed matrix size of 512×512), a 
T2-weighted fluid-attenuated inversion recovery (TR/TE/TI 5,000 ms/394 ms/1,800 ms, 0.98×
0.98×1.26-mm acquisition voxel, 0.49×0.49×1.00-mm reconstructed voxel, 176 continuous 
slices, acquisition matrix size of 250×250, and reconstructed matrix size of 512×512), and a 
gradient recalled echo pulse sequence with susceptibility-weighted imaging. The protocols for 
MRI acquisition and analysis are in line with current imaging standards (STandards for 
ReportIng Vascular changes on nEuroimaging [STRIVE], version 2) 19. 
T1-weighted images and T2-weighted fluid-attenuated inversion recovery images are used 
to identify WMHs by use of an International Organization for Standardization (ISO)-13485 
2012-certified automated method (which includes visual inspection) 38. Numbers of all WMHs 
identified are summed for assessment of total WMH burden in milliliters. Periventricular WMHs 
are automatically defined as WMHs less than 3 mm from the cerebrospinal fluid and deep 
cortical WMHs as WMHs 3 or more mm from the cerebrospinal fluid 39. This method has a small 
chance of misclassifying juxtacortical WMHs, which are relatively uncommon 40, as 
periventricular WMHs. The location and number of lacunar infarcts are manually rated on T2 
and fluid-attenuated inversion recovery images and defined as focal lesions of ≥3 mm and 
<15 mm in size with a similar signal intensity as cerebrospinal fluid on all sequences and a 
hyperintense rim 19. The location and number of cerebral microbleeds are manually rated on 
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3-dimensional T2∗  gradient recalled echo-weighted imaging with susceptibility-weighted 
imaging by means of the Microbleed Anatomical Rating Scale 41 and defined as focal lesions of 
≥2 mm and ≤10 mm in size with a hypointense signal on T2∗  gradient recalled echo- and 
susceptibility-weighted images 19. Three neuroradiologists perform the rating of lacunar infarcts 
and cerebral microbleeds. 
Endothelial glycocalyx thickness 
The glycocalyx is a gel layer on the luminal side of endothelial cells which prevents blood cells 
from penetrating or adhering to the vessel wall. Impaired glycocalyx function would allow more 
red blood cells (RBCs) to penetrate deeper towards the endothelial surface, which may 
influence endothelial function 42. We use the Glycocheck system (Microvascular Health 
Solutions, Inc., Salt Lake City, Utah) to measure glycocalyx thickness in the sublingual 
microcirculation (Figure 2.1E). After calibration, the lens is placed against the lingual frenum 
near the tongue base with limited pressure. The sidestream dark field camera uses green 
light-emitting diodes (540 nm) to detect the hemoglobin of passing RBCs. All measurable 
vessels are identified, recorded, and analyzed automatically. Vessels with RBC columns larger 
than 30 μm in diameter or high tortuosity are excluded. 
The results of analyses are presented as the perfused boundary region (μm), which is 
calculated as the distance between the outer boundaries of the erythrocytes and the center 
lumen of the vessel ((perfused diameter-median RBC column width)/2) 20. It reflects the 
dynamic lateral position of RBCs. Then the calculated perfused boundary region values, 
classified according to their corresponding RBC column widths between 5 μm and 25 μm, 
are averaged to provide a single perfused boundary region value for each participant. 
Plasma and urine biomarkers 
Since microvascular endothelium covers approximately 98% of the total vascular surface area 
and synthetic capacity 21, plasma or serum biomarkers of endothelial function, such as soluble 
vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1, soluble E-selectin, 
and von Willebrand factor, can be regarded as reflecting mainly microvascular endothelial 
function. Among these, soluble vascular cell adhesion molecule-1, soluble intercellular 
adhesion molecule-1, and soluble E-selectin are measured in ethylenediaminetetraacetic acid 
plasma samples with commercially available 4-plex sandwich immunoassay kits (Meso Scale 
Discovery, Rockville, Maryland) as described previously 43. Von Willebrand factor is quantified 
in citrate plasma using an enzyme-linked immunosorbent assay (Dako Denmark A/S, Glostrup, 
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Denmark). Concentrations of von Willebrand factor are expressed as a percentage of von 
Willebrand factor detected in pooled citrated plasma of healthy volunteers (Figure 2.1F). 
Albuminuria can be regarded as a marker of generalized endothelial dysfunction 3. To 
assess urinary albumin excretion, participants are requested to collect two 24-hour urine 
samples (Figure 2.1G). Urinary albumin concentration is measured with a standard 
immunoturbidimetric assay by means of an automatic analyzer (Beckman Synchron LX20; 
Beckman Coulter, Inc., Brea, California) and multiplied by collection volume to obtain 24-hour 
urinary albumin excretion. A urinary albumin concentration below the detection limit of the 
assay (2mg/L) is set at 1.5 mg/L before multiplying by collection volume. Only urine collections 
with a collection time between 20 hours and 28 hours are considered valid. If needed, urinary 
albumin excretion is extrapolated to a 24-hour excretion. Microalbuminuria is defined as a 
24-hour albumin excretion of 30-300 mg/24 hours, and macroalbuminuria is defined as a 
24-hour albumin excretion greater than 300 mg/24 hours. These definitions are preferably 
based on the average of two 24-hour urine collections (available for approximately 90% of the 
participants). 
Validation of measurements 
Validation of measurements is described in the Supplemental Material. 
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Results 
Currently, we have carried out a number of cross-sectional investigations involving 
microvascular measurements within the framework of The Maastricht Study and have found 
that multiple cardiovascular risk factors (age, sex, blood pressure, waist circumference, etc.) 
and diseases (e.g., (pre)diabetes and depression) are associated with microvascular 
(dys)function. The findings are summarized in Tables 2.2 and 2.3. 
Cardiovascular risk factors and microvascular function 
MVD may be a common pathological phenomenon in cardiovascular diseases that is induced 
by multiple risk factors. In a preliminary study with a limited number of participants, we used 
skin flowmotion measurement and found that older age and higher 24-hour systolic blood 
pressure were associated with a higher total SMF energy, while greater waist circumference 
and body mass index (weight (kg)/height (m)2) were associated with a lower total SMF energy 
44. Further analysis of the 5 frequency components revealed associations of older age with 
higher energy contributions of the respiratory and cardiac components and of higher 24-hour 
systolic blood pressure with higher energy contributions of all 5 frequency components, as well 
as associations of greater waist circumference with lower energy contributions of all of the 
frequency components 44. 
Evaluating microvascular responses in skin and retina, we observed that older age and 
higher plasma glucose level were associated with both lower heat-induced skin hyperemia and 
lower flicker light-induced retinal arteriolar dilation 45, 46. In addition, lower heat-induced skin 
hyperemia was found in men and in current smokers 45. Interestingly, we did not find any 
association of 24-hour systolic blood pressure with microvascular responses in skin or retina. 
Instead, higher 24-hour pulse pressure was associated with lower heat-induced skin hyperemia, 
and higher 24-hour diastolic blood pressure was associated with increased flicker light-induced 
retinal arteriolar dilation 45. Higher plasma glucose level was associated with the presence of 
brain lacunar infarcts and larger volumes of WMHs, including deep cortical and periventricular 
WMHs, but not with the presence of cerebral microbleeds 47. 
In addition, arterial stiffening as determined by carotid-femoral pulse wave velocity was not 
associated with skin capillary density or recruitment, skin flowmotion, or heat-induced skin 
hyperemia, as demonstrated in analyses carried out in both The Maastricht Study and 
Supplementation en Vitamines et Mineraux Antioxydants 2 (SU.VI.MAX2) Study cohorts 48. 
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Chronic diseases and microvascular function 
The “ ticking clock”  hypothesis postulates that the clock for coronary heart disease 
development starts ticking before the onset of clinical diabetes 49. Similarly, T2DM-associated 
MVD may occur long before T2DM is diagnosed. In view of this, we studied the association 
between glucose metabolism status and MVD. We found that both impaired flicker 
light-induced retinal arteriolar dilation and heat-induced skin hyperemia have already occurred 
in prediabetes (defined as impaired fasting glucose concentration and/or impaired glucose 
tolerance), and both impairments were more severe in established T2DM 46. Prediabetes and 
T2DM were also associated with markers of cerebral small-vessel disease, including the 
presence of lacunar infarcts, and larger volumes of WMHs, as compared with normal glucose 
metabolism 47. In contrast, there were no significant associations of prediabetes and T2DM with 
the presence of cerebral microbleeds 47. To explore the underlying mechanism of 
(pre)diabetes-associated MVD, we further performed mediation analysis and found that, 
among hyperglycemia, insulin resistance, blood pressure, lipid profile, and low-grade 
inflammation, hyperglycemia was the main mediator of both the prediabetes-associated and 
T2DM-associated skin and retinal MVD, with a mediation effect of approximately 50%-75% 50. 
Depression and cognitive decline are thought to be partly related to MVD 51. In a recent 
meta-analysis, we provided evidence that not only cerebral forms of MVD but also peripheral 
MVD, as measured by plasma biomarkers, is associated with incident depression 6. In The 
Maastricht Study, we also found higher levels of plasma markers of endothelial dysfunction to 
be associated with the presence of depressive disorder and a higher depressive symptom 
score 43. With regard to cognitive function, albuminuria, defined as urinary albumin excretion ≥
30 mg/24 hours, was associated with lower information processing speed, independent of 
educational level, cardiovascular risk factors, and lifestyle factors 52. This association tended to 
be stronger in older individuals 52. 
Albuminuria, normally considered a measure of kidney dysfunction, is also thought to 
reflect generalized endothelial dysfunction. However, this hypothesis has been tested only with 
indirect measurements, such as plasma biomarkers of endothelial function 53, 54.  
Chapter 2 Microvascular Phenotyping in The Maastricht Study 
 36 
Chapter 2 Microvascular Phenotyping in The Maastricht Study 
 37 
Therefore, we examined the association of direct measurements of MVD in skin and retina with 
albuminuria. We found that lower skin capillary recruitment following arterial and venous 
occlusion was associated with the presence of albuminuria 55. Lower flicker light-induced retinal 
arteriolar dilation was also associated with albuminuria, and this association was stronger in 
persons with T2DM. In addition, the association of lower heat-induced skin hyperemic response 
with albuminuria was present in persons with T2DM only 56. These findings suggested an 
interaction effect of T2DM on the association between direct measurements of MVD and 
albuminuria. 
Discussion 
For the development of both prevention and treatment strategies in the general population, we 
need solid epidemiologic data. To our knowledge, no population-based study has applied a 
wide scope of microvascular morphological and functional phenotyping. Most studies have 
applied, at most, a few of the microvascular measurements discussed here, including plasma 
biomarkers, retinal microvascular diameters, and cerebral small-vessel disease 2,6. In The 
Maastricht Study 22, we combine an array of microvascular measurements in different vascular 
beds (e.g., low and high flow impedance) with extensive phenotyping of biometric factors, 
lifestyle and cardiovascular risk factors, and diseases. This approach allows us to study not 
only the role of generalized MVD in the development and progression of various diseases with 
a systems physiology approach but also MVD, which is specific for certain organs/tissues. 
In The Maastricht Study, we have observed associations of MVD with cardiovascular risk 
factors, (pre)diabetes, depression, cognitive function, and albuminuria. These results suggest 
that 1) microvascular function is determined by multiple cardiovascular risk factors 44-47, 2) MVD 
occurs prior to the diagnosis of T2DM 46, 47, 3) MVD is a systemic pathophysiological 
phenomenon in T2DM, and 4) MVD is associated with (end)organ dysfunction (e.g., depression, 
cognitive decline, albuminuria) 43, 52, 55, 56. 
Strengths of the Maastricht Study 
The combination of an array of microvascular measurements and the extensive phenotyping in 
The Maastricht Study has several strengths. First, the size of the study population in 
conjunction with the extensive phenotyping enables detection of independent associations after 
extensive adjustment for potential confounders. Second, the standard operating procedures 
and the quality control over time enhance the consistency of the microvascular 
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measurements and increase their usability in other studies. Third, the use of multiple 
microvascular measurements enables comparison of changes in the microvasculature across 
arterioles, capillaries, and venules, as well as across territories, in order to disentangle the 
influence of risk factors/diseases on the microvasculature as well as the heterogeneity of the 
microvasculature responding to different (patho)physiological situations 57.  
Longitudinal studies 
Currently, annual follow-up on disease incidence and mortality is being performed in The 
Maastricht Study, which will enable longitudinal analyses. Through the cross-sectional studies, 
we have already found that MVD in multiple territories is present before the diagnosis of T2DM 
(prediabetes), which implies that MVD is not only a consequence of T2DM but also an essential 
factor that can precede T2DM and increase the risk of its complications and comorbidities, 
which are partly of microvascular origin. To confirm this, longitudinal studies are planned to 
investigate the association of MVD with the incidence of various diseases, such as T2DM, 
cardiovascular diseases, and cerebral diseases. In addition, microvascular measurements will 
be included in the follow-up procedure to investigate the microvascular changes with 
development and progression of diseases. 
Fully automated analysis of microvascular imaging 
Several microvascular measurements are based on imaging, of which the analyses are often 
performed manually. To apply such measurements efficiently in a population-based setting 
requires fully automated analysis software. Recent technical advances have enabled a 
transition from manual/semi-automated image analysis to fully automated image analysis and 
have made this approach more precise and time-saving (e.g., the software for detecting brain 
WMHs in The Maastricht Study) 38. In addition, this approach allows identification, extraction, 
and investigation of novel microvascular features, such as retinal microvascular tortuosity, 
fractal dimension, and bifurcation features. These developments provide for a more 
comprehensive observation of microvascular changes as well as better availability and 
implementation of the microvascular measurements in a large population, for either research or 
clinical use. Further, the protocols involving image acquisition, processing, and analysis should 
be standardized across studies, and reproducibility and validity should be carefully documented, 
for use by other researchers and further applications. 
The first wave of data collection in The Maastricht Study (including more than 9,000 
participants) continued through 2019. Next, we plan to start follow-up surveys in the same 
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cohort. In the coming years, we will develop, validate, and implement fully automated image 
analysis applications. In that way, a wealth of different microvascular morphological and 
functional markers of different territories will become available. It is important to assess the 
associations and role of MVD in relation to disease development in order to assess whether 
interventions against MVD should be developed for prevention purposes.
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Supplemental Material to Chapter 2 
Study population and design 
The microvascular studies are conducted within the framework of The Maastricht Study, an 
ongoing observational prospective population-based cohort study. The rationale and 
methodology have been described previously 1. In brief, the study focuses on the etiology, 
pathophysiology, complications and comorbidities of type 2 diabetes mellitus (T2DM) and is 
characterized by an extensive phenotyping approach. Eligible for participation are all 
individuals aged between 40 and 75 years and living in the southern part of the Netherlands. 
The baseline assessment started in November 2010 and is currently ongoing. An annual 
follow-up on disease incidence and mortality is in progress. The study has been approved by 
the institutional medical ethical committee (NL31329.068.10) and the Netherlands Health 
Council under the Dutch “Law for Population Studies” (permit 131088-105234-PG). All 
participants give written informed consent. 
Data collection  
All measurements are executed by trained research assistants according to standardized 
protocols. In principle, all procedures apply to all participants included, unless clinically 
contraindicated. Participants are studied while on medication. All participants are asked to 
refrain from smoking and drinking caffeine-containing beverages 3 hours before the 
measurement. A light meal (breakfast or lunch), low in fat content, is allowed at least 90 
minutes before the start of the measurements. Room temperature is kept at 24℃. General and 
disease-specific measurements have been illustrated elsewhere 1. 
Validation of the microvascular measurements  
For the quantification of skin capillary density and recruitment, a semi-automatic image analysis 
application (CapiAna) has been developed. Analyses with CapiAna have a good consistency 
with the manual counting procedure, with a Pearson's correlation coefficient (r) of 0.95 
(p<0.001) and a Deming regression coefficient of 1.01 (95% confidence interval (CI): 0.91, 1.10) 
2. Overall intra- and interobserver coefficients of variation for CapiAna were 2.5% and 5.6%, 
respectively 2. For the heat-induced skin hyperemic response, the interobserver correlation 
coefficient of the hyperemic curves (n=1,760) between two observers was 0.839 3. For retinal 
microvascular reactivity, interobserver correlation coefficient of retinal arteriolar baseline 
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diameter, venular baseline diameter, percentage arteriolar dilation, and percentage venular 
dilation (n=9) between two randomly selected observers were 0.980, 0.972, 0.796, and 0.871, 
respectively. For retinal microvascular diameters, the intraclass correlation coefficient for the 
central retinal arteriolar equivalent (CRAE) was 0.910 and that for the central retinal venular 
equivalent (CRVE) was 0.897 between RHINO software analyses with manual identification of 
arterioles and venules versus without it. We also calculated relative errors, which were 3.91% 
(5 acquisitions of 12 subjects) and 5.00% (5 acquisitions of 12 subjects) for CRAE and CRVE, 
respectively 4. For cerebral small vessel disease, the interclass correlation coefficients of 
lacunar infarcts and cerebral microbleeds (n=50) between 3 observers were 0.84 (95% CI: 0.74, 
0.91) and 0.83 (95% CI: 0.72, 0.90), respectively 5. With regard to plasma biomarkers, intra- 
and interassay coefficients of variation were 3.5% and 5.9%, respectively, for soluble vascular 
cell adhesion molecule-1 (sVCAM-1), 2.5% and 5.3% for soluble intercellular adhesion 
molecule-1 (sICAM-1), 6.4% and 6.0% for soluble E-selectin, and 3.2% and 5.4% for von 
Willebrand factor. 
For the glycocalyx thickness measurements we use the standardized approach of the 
Glycocheck device. Previous studies have reported an interclass correlation coefficient of 
endothelial glycocalyx thickness between the physician’s measurements of 0.77 (95% CI: 0.52, 
0.89) 6. 
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Abstract 
Background 
Retinal microvascular diameters are biomarkers of cardio-metabolic risk. However, the 
association of (pre)diabetes with retinal microvascular diameters remains unclear. We aimed 
to investigate the association of prediabetes (impaired fasting glucose or impaired glucose 
tolerance) and type 2 diabetes with retinal microvascular diameters in a predominantly white 
population. 
 
Methods 
In a population-based cohort study with oversampling of type 2 diabetes (N=2876; n=1630 
normal glucose metabolism [NGM], n=433 prediabetes and n=813 type 2 diabetes, 51.2% 
men, aged 59.8±8.2 years; 98.6% white), we determined retinal microvascular diameters 
(measurement unit as measured by retinal health information and notification system [RHINO] 
software) and glucose metabolism status (using OGTT). Associations were assessed with 
multivariable regression analyses adjusted for age, sex, waist circumference, smoking, 
systolic blood pressure, lipid profile and the use of lipid-modifying and/or antihypertensive 
medication. 
 
Results 
Multivariable regression analyses showed a significant association for type 2 diabetes but not 
for prediabetes with arteriolar width (versus NGM; prediabetes: B=0.62 [95%CI -1.58, 2.83]; 
type 2 diabetes: 2.89 [0.69, 5.08]; measurement unit); however, there was a linear trend for the 
arteriolar width across glucose metabolism status (p for trend=0.013). The association with 
wider venules was not statistically significant (prediabetes: 2.40 [-1.03, 5.84]; type 2 diabetes: 
2.87 [-0.55, 6.29], p for trend=0.083; measurement unit). Higher HbA1c levels were associated 
with wider retinal arterioles (standardized B=0.043 [95%CI 0.00002, 0.085]; p=0.050) but the 
association with wider venules did not reach statistical significance (0.037 [-0.006, 0.080]; 
p=0.092) after adjustment for potential confounders. 
 
Conclusions 
Type 2 diabetes, higher levels of HbA1c and, possibly, prediabetes, are independently 
associated with wider retinal arterioles in a predominantly white population. These findings 
indicate that microvascular dysfunction is an early phenomenon in impaired glucose 
metabolism. 
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Introduction 
The worldwide epidemic of diabetes and its complications necessitates identification of early 
pathophysiological changes in the development of complications, as an essential requirement 
for risk assessment as well as for the design of interventions. 
In recent studies, retinal microvascular diameters have been shown to be closely related 
to incidence of complications of diabetes, including retinopathy, nephropathy and stroke 1,2, 
suggesting a role for early retinal changes in assessment of risk of these complications. 
However, the association of (pre)diabetes with retinal microvascular diameters remains 
unclear. Although type 2 diabetes has been associated with wider retinal arterioles in the 
majority of studies, an association of type 2 diabetes with wider retinal venules has only been 
found in non-white individuals 3–9. Moreover, few studies have investigated the association of 
prediabetes with retinal microvascular diameters; those that have, also found that prediabetes 
was associated with wider retinal venules in non-white individuals only 3–6. However, these 
studies 3–6 had significant limitations. For example, only one study used the gold standard of 
oral glucose tolerance test (OGTT), rather than fasting glucose level or random glucose level, 
to define prediabetes and diabetes in a multi-ethnic population 5. In addition, none adjusted for 
use of medication that is associated with glucose metabolism and microvascular function, such 
as antihypertensive drugs. 
As it has been suggested that (pre)diabetes may be associated with both wider retinal 
arterioles and venules, the question arises whether, and, if so, how, these changes are related. 
Theoretically, wider arterioles could lead to wider venules via transmittance of greater 
microvascular pressure. Alternatively, or additionally, wider venules (if they are proven to be a 
marker for arteriole-venule shunting) could lead to wider arterioles through local tissue hypoxia. 
Recent studies on a multi-ethnic Asian population found that the association of (pre)diabetes 
with wider retinal arterioles was independent of retinal venular diameters, while the association 
with wider retinal venules was not independent of retinal arteriolar diameters 4,7,8, which 
supports the hypothesis that (pre)diabetes-associated retinal venular dilation is linked to retinal 
arteriolar dilation. However, these associations have not been studied in a white population. 
Therefore, in this population-based cohort study, we investigated the associations of 
OGTT-based glucose metabolism status (normal glucose status, prediabetes, type 2 diabetes) 
and measures of blood glucose with retinal microvascular diameters in a predominantly white 
population, taking into account a broad array of potential confounders. In addition, we explored 
whether retinal arteriolar and venular diameters were mutually related. 
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Methods 
Study population and design 
We used data from The Maastricht Study, an observational, prospective population based 
cohort study. The rationale and methodology have been described previously 10. In brief, the 
study focuses on the etiology, pathophysiology, complications and comorbidities of type 2 
diabetes, and is characterized by an extensive phenotyping approach. All individuals aged 
between 40 and 75 years and living in the southern part of the Netherlands were eligible to 
participate. Participants were recruited through mass media campaigns and from the 
municipal registries and the regional Diabetes Patient Registry by postal mailing. Recruitment 
was stratified according to known type 2 diabetes status, with an oversampling of individuals 
with type 2 diabetes for reasons of efficiency. The present report includes cross-sectional data 
from the first 3451 participants, who completed the baseline survey between November 2010 
and September 2013. The baseline examinations of each participant in the study were 
performed within a time window of 3 months (except for some participants in whom fundus 
photography was initially unavailable or in whom photos were of low quality; in these 
participants, fundus photography was obtained later; see below). The study was approved by 
the medical ethical committee of the Maastricht University Medical Center (NL31329.068.10) 
and the Minister of Health, Welfare and Sports of the Netherlands (permit 131088-105234-PG). 
All participants gave written informed consent. From the initial 3451 participants included, 
those with types of diabetes other than type 2 diabetes were excluded (n=41). Of the 
remaining 3410 participants, retinal microvascular diameter data were available for 2924 
participants, 48 of whom had data missing for one or more covariates. The main reasons for 
missing data were logistic (no equipment, no trained researcher available or technical failure), 
contraindications for the eye drops or fundus photographs of insufficient quality. The retinal 
microvascular diameter study population thus consisted of 2876 participants (Supplemental 
Figure S3.1); fundus photography was obtained within the time window of 3 months in 2700 
participants and after a mean of 47 months (range 34-57) after the date on which the retinal 
measurement was planned in 176 participants. 
Assessment of glucose metabolism status 
To assess glucose metabolism status, all participants (except those who used insulin) 
underwent a standardized 2-hour 75 g OGTT after an overnight fast. For safety reasons, 
participants with a fasting glucose level above 11.0 mmol/L, as determined by a finger prick 
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test, did not undergo the OGTT. For these individuals, fasting glucose level and information 
about diabetes medication use were used to assess glucose metabolism status. Glucose 
metabolism status was defined according to the WHO 2006 criteria as normal glucose 
metabolism (NGM, fasting glucose<6.1 mmol/L; 2-hour postload glucose<7.8 mmol/L), 
impaired fasting glucose and/or impaired glucose tolerance (combined as prediabetes, fasting 
glucose 6.1-7.0 mmol/L or 2-hour postload glucose 7.8-11.1 mmol/L) and type 2 diabetes 
(fasting glucose≥7.0 mmol/L or 2-hour postload glucose≥11.1 mmol/L) 11. 
Retinal photography and measurement of retinal microvascular diameters 
All participants were asked to refrain from smoking and drinking caffeine-containing beverages 
for 3 hours before the measurement. Participants were allowed to consume a light meal 
(breakfast or lunch) low in fat content at least 90 minutes before the start of the measurement 
12. For retinal measurements, fundus photography of both eyes was performed 15 minutes 
after the pupils had been dilated with tropicamide 0.5% and phenylephrine 2.5% (wt/vol.). 
All fundus photographs were taken with an auto-focus, auto-shot and auto-tracking fundus 
camera (Model AFC-230; Nidek, Gamagori, Japan) in an optic disc-centered field of view of 
45° in a darkened room. Static retinal vessel analysis (one image of the left or right eye was 
randomly chosen per participant) was performed using the retinal health information and 
notification system (RHINO) software developed by the RetinaCheck group of the Technical 
University of Eindhoven (Eindhoven, the Netherlands) 13,14. Optic disc detection and 
arteriole/venule classification were corrected manually. Retinal vessel diameters were 
measured at 0.5-1.0 disc diameter away from the optic disc margin and were presented as 
central retinal arteriolar equivalent and central retinal venular equivalent (CRAE and CRVE, 
respectively) in measurement units (MU). The scale factor is based on the optic disc diameter, 
which is assumed to be 1800 μm 15, i.e., 1 MU=1 pixel size×1800 μm/pixel size of optic disc 
diameter. CRAE and CRVE represent the equivalent single-vessel parent diameter for the six 
largest arterioles and largest venules in the region of interest, respectively. The calculations 
were based on the improved Knudtson-Parr-Hubbard formula 16. 
Fundus photographs of insufficient quality, e.g., obstructed by lashes or defocused, were 
evaluated and discussed with a second observer and excluded on mutual agreement. We 
calculated the intraclass correlation coefficients for CRAE and CRVE to assess the agreement 
between analyses of the RHINO software with versus without manual identification of 
arterioles and venules using 2556 images. The intraclass correlation coefficient of CRAE was 
0.910 and that of CRVE was 0.897. 
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Measurement of general characteristics and covariates 
History of cardiovascular disease, duration of diabetes, physical activity (hours/week), 
smoking status (never, former, current) and alcohol intake (none/low/high) were assessed by 
questionnaire 10. Use of lipid-modifying, antihypertensive and glucose-lowering medication 
was assessed during a medication interview in which the generic name, dose and frequency 
were recorded 10. We measured weight, height, BMI, waist circumference, office and 
ambulatory 24-hour blood pressure, plasma glucose levels, serum creatinine, 24-hour urinary 
albumin excretion (twice), peripheral vibration perception threshold, HbA1c and plasma lipid 
profile, as described elsewhere 10. eGFR (in ml min-1 [1.73 m]-2) was calculated with the 
Chronic Kidney Disease Epidemiology Collaboration equation based on both serum creatinine 
and serum cystatin C 17. The presence of retinopathy was assessed in both eyes by use of 
fundus photographs taken with the same fundus camera (Model AFC-230; Nidek, Gamagori, 
Japan) as used for measurement of retinal microvascular diameters 10. Plasma biomarkers of 
inflammation included high-sensitivity C-reactive protein, serum amyloid A, interleukin-6, 
interleukin-8, and tumor necrosis factor-α and were measured in ethylenediaminetetraacetic 
acid plasma samples with commercially available 4-plex sandwich immunoassay kits (Meso 
Scale Discovery, Rockville, MD, USA). 
Statistical analysis 
Multiple linear regression analysis was used to determine the association of glucose 
metabolism status (NGM, prediabetes and type 2 diabetes) and measures of blood glucose 
(HbA1c, fasting glucose, 2-hour postload glucose levels) with retinal vessel diameters. For 
linear trend analyses, the categorical variable glucose metabolism status (NGM=0, 
prediabetes=1, and type 2 diabetes=2) was used in the regression models. To estimate the 
difference in retinal microvascular diameters between individuals with prediabetes and type 2 
diabetes compared with NGM, we performed analyses with dummy variables for prediabetes 
and type 2 diabetes. We used the likelihood ratio test to compare models in which glucose 
metabolism status was treated as a categorical or continuous variable 18. Model 1 was 
adjusted for age and sex; Model 2 was additionally adjusted for cardiovascular risk factors that 
have previously been associated with retinal microvascular diameters (waist circumference, 
smoking status, office systolic blood pressure, use of antihypertensive and/or lipid-modifying 
drugs, fasting triglycerides and total-to-high-density-lipoprotein [HDL] cholesterol ratio). We 
also performed a range of additional analyses (see Results for details). A standardized sum 
score was calculated for plasma markers of inflammation as follows: for each individual 
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biomarker, a z score was calculated according to the formula (individual value-population 
mean)/population standard deviation and the resulting individual biomarker z scores were then 
averaged. A p value of <0.05 was considered statistically significant. Interactions of glucose 
metabolism status and measures of blood glucose with sex and left versus right eye (with 
regard to the associations between glucose metabolism status with retinal diameters) were 
tested by incorporating interaction terms (e.g., prediabetes×sex) in the regression models. A 
p for interaction of <0.10 was considered statistically significant. Statistical analyses were 
performed by use of the Statistical Package for Social Sciences (Version 25.0; IBM, Chicago, 
IL, USA), except for the likelihood ratio test, which was performed using Stata (Version 14.1; 
StataCorp, College Station, TX, USA). 
 
Results 
Characteristics of the study population 
Table 3.1 shows the general characteristics of the study population stratified by glucose 
metabolism status. The study population consisted of 2876 individuals (98.6% white) with a 
mean age of 59.8±8.2 years; 51.2% were men, and 28.3% had type 2 diabetes (by design), 
including both previously diagnosed type 2 diabetes (24.5%) and newly diagnosed type 2 
diabetes (3.7%). Individuals with type 2 diabetes and prediabetes, compared with those with 
NGM, were older (p<0.001, ANOVA test), more often male (p<0.001, χ2 test) and a current 
smoker (p<0.001), and had a higher BMI (p<0.001), waist circumference (p<0.001), systolic 
and diastolic blood pressure (p<0.001 for both), fasting plasma glucose (p<0.001), 2-hour 
postload glucose (p<0.001), HbA1c (p<0.001) and triglycerides levels (p<0.001), lower level of 
physical activity (p<0.001) and lower eGFR (p<0.001). The group of individuals with missing 
data on retinal microvascular measurements or covariates were generally quite similar to 
those included, but had a higher total-to-HDL cholesterol ratio, more current smokers and 
insulin use, and smaller CRAE (Supplemental Table S3.1). 
Association of glucose metabolism status with retinal microvascular diameters 
Retinal arterioles were wider (CRAE measured in MU) in individuals with type 2 diabetes 
compared with those with NGM in the age- and sex-adjusted model (Model 1: B=2.29 [0.52, 
4.06]; Figure 3.1A). The association of prediabetes with CRAE was non-significant (Model 1: 
B=0.42, [95%CI -1.73, 2.57]; Figure 3.1A), whereas CRAE showed a linear trend across  
Chapter 3 Type 2 Diabetes and HbA1c are associated with Retinal Arterioles 
 54 
Table 3.1 General Characteristics of the Study Population According to Glucose Metabolism Status 
Characteristics 
NGM 
n=1630 
Prediabetes 
n=433 
Type 2 diabetes 
n=813 
Age (years)  57.9±8.1 61.6±7.5 62.6±7.7 
Women (n, %) 937 (57.5) 202 (46.7) 265 (32.6) 
Diabetes duration (years) a - - 5.0 [1.0-11.0] 
BMI (kg/m2) 25.5±3.6 27.6±4.2 29.9±5.0 
Waist circumference (cm)    
  Men 96.2±9.6 102.1±10.3 107.8±12.5 
  Women 85.8±10.0 93.0±12.7 102.0±14.2 
History of cardiovascular disease (n, %) 191 (11.7) 56 (12.9) 226 (27.8) 
Office SBP (mmHg) 130.6±17.0 137.3±16.8 142.0±18.0 
Office DBP (mmHg) 75.2±9.9 77.8±9.4 77.4±9.6 
Ambulatory 24-hour SBP (mmHg)b  117.3±10.9 120.1±11.1 122.4±12.1 
Ambulatory 24-hour DBP (mmHg)b  73.9±7.1 74.5±7.0 73.5±7.3 
Hypertension (n, %) 659 (40.4) 274 (63.3) 680 (83.6) 
Smoking (% never/former/current) 39.8/48.7/11.5 29.1/58.7/12.2 28.9/55.1/16.0 
Alcohol intake (% none/low/high) 13.6/59.2/27.3 15.2/54.7/30.0 30.6/51.0/18.3 
Physical activity (hours/week) c 6.2±4.5 5.2±4.1 4.2±3.9 
Fasting glucose (mmol/L)  5.2±0.4 5.9±0.6 7.9±2.0 
2-hour postload glucose (mmol/L)d 5.4±1.1 8.1±1.7 14.4±3.9 
HbA1c (mmol/mol)  35.9±3.7 38.6±4.5 51.9±11.2 
HbA1c (%)  5.4±0.3 5.7±0.4 6.9±1.0 
Triglycerides (mmol/L)  1.2±0.6 1.6±1.0 1.8±1.0 
Total-to-HDL cholesterol ratio 3.6±1.1 3.8±1.2 3.7±1.1 
Total cholesterol (mmol/L) 5.6± 1.0 5.5±1.1 4.4±1.0 
HDL (mmol/L) 1.7±0.5 1.5±0.4 1.3±0.4 
LDL (mmol/L) 3.4±0.9 3.3±1.0 2.4±0.9 
Antihypertensive medication use (n, %) 364 (22.3) 199 (46.0) 598 (73.6) 
Lipid-modifying medication use (n, %) 270 (16.6) 154 (35.6) 609 (74.9) 
Diabetes medication use (n, %) 0 (0) 0 (0) 641 (78.8) 
  Insulin - - 167 (20.5) 
  Oral medication only - - 600 (73.8) 
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Table 3.1 continued 
Characteristics 
NGM 
n=1630 
Prediabetes 
n=433 
Type 2 diabetes 
n=813 
eGFR (ml min–1[1.73 m]-2) 90.3±13.1 86.7±14.3 84.8±16.9 
Albuminuria (n, %) e  66 (4.1) 29 (6.7) 148 (18.4) 
Retinopathy (n, %) 1 (0.1) 1 (0.2) 34 (4.3) 
Neuropathy (n ,%) f 93 (6.4) 37 (9.9) 147 (20.5) 
CRAE (MU)     
  Crude 142.9±20.1 141.2±20.2 142.0±21.0 
  Age- and sex-adjusted 156.0±0.49 156.3±0.94 158.1±0.73 
  Age-,sex-and office SBP-adjusted 173.1±0.48 174.0±0.93 176.2±0.73 
CRVE (MU)     
  Crude 213.9±30.7 215.9±31.4 215.6±32.5 
  Age- and sex-adjusted 223.0±0.75 226.5±1.50 227.2±1.13 
  Age-, sex- and office SBP-adjusted 228.1±0.75 231.8±1.50 232.6±1.13 
Data are reported as mean±SD or n (%) as appropriate, except diabetes duration, which is reported as median 
[interquartile range], and adjusted CRAE and CRVE which are reported as mean±SEM 
Data present the study population for regression models 1 and 2 
CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; DBP, diastolic blood 
pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, 
low density lipoprotein; MU: Measurement unit; SBP, systolic blood pressure  
a Available for 673 individuals with type 2 diabetes; b Available for 722 individuals with type 2 diabetes; c Available 
for 685 individuals with type 2 diabetes; d Available for 623 individuals with type 2 diabetes; e Albuminuria was 
defined as a urinary albumin excretion of > 30 mg per 24 hours; f Neuropathy was defined as a vibration 
perception threshold >25 V; data were available for 718 individuals with type 2 diabetes 
 
glucose metabolism status (Model 1: p for trend=0.013; p for likelihood ratio test=0.49). After 
further adjustment for cardiovascular risk factors (Model 2), the difference in CRAE between 
type 2 diabetes and NGM became somewhat larger (prediabetes B=0.62 [-1.58, 2.83]; type 2 
diabetes B=2.89 [0.69, 5.08]; Figure 3.1A). The linear trend for CRAE across glucose 
metabolism status remained (Model 2: p for trend=0.013; p for likelihood ratio test=0.43). 
    Retinal venules were wider (CRVE measured in MU) in individuals with prediabetes and 
type 2 diabetes, compared with those with NGM, in the age- and sex-adjusted model (Model 1: 
prediabetes B=3.84 [0.50, 7.18]; type 2 diabetes B=4.68 [1.93, 7.43]; Figure 3.1B), and the 
CRVE showed a linear trend across glucose metabolism status (Model 1: p for trend=0.001; p 
for likelihood ratio test=0.36). The difference in CRVE was attenuated and non-significant after 
adjustment for cardiovascular risk factors (Model 2: prediabetes B=2.40 [-1.03, 5.84]; type 2 
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diabetes B=2.87 [-0.55, 6.29]; Figure 3.1B). CRVE no longer showed a linear trend across 
glucose metabolism status (Model 2: p for trend=0.083; p for likelihood ratio test=0.55). 
 
Figure 3.1 Multivariable-adjusted differences in retinal microvascular diameters between individuals with 
prediabetes and type 2 diabetes compared with NGM. (A) Difference in CRAE. (B) Difference in CRVE. Point 
estimates (B) and 95%CIs represent the difference in retinal microvascular diameters in CRAE and CRVE as 
compared with NGM. NGM is the reference and is set to zero. Model 1: adjusted for age and sex; Model 2: 
additional adjustment for waist circumference, smoking status, systolic blood pressure, triglycerides, total-to-HDL 
cholesterol ratio, and use of antihypertensive and/or lipid-modifying drugs. PreD, prediabetes; T2D, type 2 
diabetes; MU, measurement unit. *p<0.05 ** p<0.01 ***p<0.001 versus NGM in corresponding model 
 
Associations of measures of blood glucose with retinal microvascular diameters 
Higher levels of HbA1c were associated with greater CRAE after adjustment for age and sex 
(Model 1; Figure 3.2A and 3.3A), and also after further adjustment for cardiovascular risk 
factors (Model 2; Figure 3.2A). Higher levels of fasting glucose and 2-hour postload glucose 
were not statistically significantly associated with greater CRAE (Figure 3.2A). 
Higher levels of HbA1c were associated with greater CRVE after adjustment for age and 
sex (Model 1; Figure 3.2B and 3.3B). The association was attenuated and non-significant after 
further adjustment for cardiovascular risk factors (Model 2; Figure 3.2B). Higher fasting 
glucose and 2-hour postload glucose were not statistically significantly associated with greater 
CRVE (Figure 3.2B). 
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Figure 3.2 Multivariable-adjusted associations of measures of blood glucose with retinal microvascular 
diameters. (A) Associations of measures of blood glucose with CRAE. (B) Associations of measures of blood 
glucose with CRVE. Point estimates (standardized B [stB]) and 95%CIs represent the difference (in SD) in retinal 
microvascular diameters per SD increase in the measure of blood glucose. Model 1: adjusted for age and sex; 
Model 2: additional adjustment for waist circumference, smoking status, systolic blood pressure, triglycerides, 
total-to-HDL cholesterol ratio, and use of antihypertensive and/or lipid-modifying drugs. Model 3: additional 
adjustment for CRVE in models of CRAE and adjustment for CRAE in models of CRVE 
Additional analyses 
Further analyses to assess the robustness of our observations are described in the 
Supplemental Material (Supplemental Tables S3.2-S3.7); in general, these analyses 
confirmed the observations reported above. To explore whether retinal diameters are 
intrinsically linked, we analyzed venular diameters as a function of arteriolar diameters. We 
found that retinal arteriolar diameters were positively associated with retinal venular diameters 
after adjustment for age and sex (B=1.09 [1.05, 1.13], p<0.001; Supplemental Figure S3.2). 
The association remained similar after further adjustment for height, body surface area, 
systolic blood pressure and HbA1c level (B=1.09 [1.05, 1.13], p<0.001). In addition, to explore 
whether the associations of glucose metabolism status and measures of blood glucose with 
CRAE and CRVE are linked, we additionally adjusted for CRVE in models of CRAE and for 
CRAE in models of CRVE. We found that further adjustment for CRVE attenuated the 
difference in CRAE in prediabetes and type 2 diabetes versus NGM (prediabetes B= -0.46 
[-2.03, 1.11]; type 2 diabetes B=1.60 [0.03, 3.16]; p for trend=0.073), while further adjustment 
for CRAE completely eliminated the difference in CRVE (prediabetes B=1.72 [-0.73, 4.18]; 
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type 2 diabetes B=-0.28 [-2.73, 2.16]; p for trend=0.984). Similarly, the association of HbA1c 
with CRAE was attenuated after further adjustment for CRVE, while the association with 
CRVE was eliminated after further adjustment for CRAE (Model 3; Figure S3.2). 
We did not find any significant associations between duration of type 2 diabetes and 
retinal microvascular diameters (available for n=673 individuals; Supplemental Tables S3.8). 
 
 
Figure 3.3 Age- and sex-adjusted association of HbA1c with retinal microvascular diameters. (A) 
Association between HbA1c and CRAE (B=0.09 95%CI [0.02, 0.17]); (B) Association between HbA1c and CRVE 
(B=0.22 [0.10, 0.34]). Regression coefficients (B) indicate the age- and sex-adjusted mean difference and 95%CI 
in CRAE and CRVE per 1 mmol/mol increase in HbA1c 
 
Discussion 
This study shows that type 2 diabetes, higher levels of HbA1c and, possibly, prediabetes are 
associated with wider retinal arteriolar diameters in a predominantly white population. Notably, 
the associations with retinal arteriolar diameters are independent of a broad array of potential 
confounders. These findings indicate that retinal microvascular changes already occur prior to 
the diagnosis of type 2 diabetes. In addition, retinal arteriolar diameters are associated with 
retinal venular diameters, independently of age, sex, height, body surface area, blood 
pressure and blood glucose, which suggests a close link between arteriolar and venular 
dilation in general and, thus, also in (pre)diabetes. 
Our results indicate that type 2 diabetes and, possibly, prediabetes are independently 
associated with wider retinal arteriolar diameters, which is consistent with previous 
cross-sectional studies 3-9. Compared with these studies, we used OGTT and HbA1c, which 
are more accurate measurements for classifying glucose metabolism status than measuring 
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fasting glucose, random glucose, and HbA1c levels only 19. In addition, we showed that the 
associations were independent of a broad array of cardiovascular risk factors. Notably, we 
found that age, sex and systolic blood pressure had strong confounding effects. For example, 
older age, male sex and higher blood pressure were associated with both narrower arterioles 
and (pre)diabetes. Unsurprisingly, eliminating these confounders through statistical 
adjustment reversed the direction of association between (pre)diabetes and retinal arteriolar 
diameters (Table S3.1). Note also that we included ambulatory 24-hour blood pressure as a 
confounder in our additional analyses, as it is more accurate than office blood pressure 20 and 
has not been used in previous studies 3-9, making residual confounding by inaccurately 
measured blood pressure much less likely in our study. With regard to the outcomes, we 
measured diameters with semi-automated software (RHINO), which was validated manually 
and had a relative error that was comparable to that of Interactive Vessel Analysis (IVAN) 
software 21. Finally, we used linear trend analyses, as we hypothesized that the difference in 
retinal microvascular diameters from NGM to prediabetes to type 2 diabetes is of a continuous 
nature. The results of these analyses favor the interpretation that arteriolar widening occurs in 
both type 2 diabetes and prediabetes. In support of this, HbA1c, a continuous measure of 
blood glucose, was significantly associated with retinal arteriolar diameters. Although we 
cannot exclude the possibility that there is no true association between prediabetes and 
greater arteriolar diameter, we attribute the lack of statistical significance of the difference 
between prediabetes and NGM with regard to retinal arteriolar diameters to a type 2 statistical 
error, because the power of between-group comparisons was reduced compared with the 
power of trend analyses. 
Retinal arteriolar dilation in (pre)diabetes is thought to be a result of impaired arteriolar 
autoregulation 22. Lacking neuronal innervation, retinal arterioles are affected mainly by local 
autoregulation through the release of vasoactive substances by microvascular endothelium 
and the myogenic response of smooth muscle cells 23. For example, in retinal arteriolar smooth 
muscle cells, hyperglycemia and hypoxia can cause endothelin-1 resistance and inhibit Ca2+ 
influx channels 24, 25. In addition, death and insufficient renewal of endothelial cells, smooth 
muscle cells and pericytes can further weaken arteriolar wall and boost dilation. 
The associations of prediabetes and type 2 diabetes with retinal venular diameters were 
directionally similar to those for arterioles even though they were not statistically significant 
after adjustment for cardiovascular risk factors. The nonsignificance of the associations may 
be explained by four factors. First, the relatively larger measurement error of venular versus 
arteriolar diameters 21 decreases the precision of the association with blood glucose and thus 
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increases the confidence interval 26. Second, our additional analyses (Figure 3.2 and 
Supplemental Figure S3.2) are consistent with the concept that (glucose-related) arteriolar 
widening drives venular widening to an important extent, possibly by greater transmission of 
blood pressure. Such mediation will tend to bias the association between blood glucose and 
venular diameters towards the null 27. Third, longitudinal studies 28-30 have suggested that 
widening of retinal venules may also occur before prediabetes, which may reduce the 
difference in venular diameter between (pre)diabetes and NGM. Fourth, our fully adjusted 
model may have been over-adjusted as a result of the inclusion of waist circumference, since 
obesity may be on the causal pathway between (pre)diabetes and retinal venular dilation 31. 
In general, studies on the associations between diabetes or blood glucose and retinal 
venular diameters have not shown consistent results 3–9, although venular widening has been 
much more consistently observed among Asian populations 3,4,6-8 than among white 
populations 3, 5, 9. These inconsistent results may be attributed to ethnicity but also to 
differences in classification of glucose metabolism status, insufficient adjustment for 
confounding and different types of software used. 
The pathophysiological mechanisms that explain retinal venular dilation in (pre)diabetes 
remain unclear. Retinal venules have been proposed to dilate in response to 
diabetes-associated inflammation 3,32, but the association was unchanged after adjustment for 
inflammation in our study and a previous study 3. As alluded to above (Figure 3.2 and 
Supplemental Figure S3.2), our results are consistent with the hypothesis that retinal venular 
dilation is, at least in part, a direct consequence of arteriolar dysfunction 24. However, we 
cannot exclude the possibility that, alternatively or additionally, wider venules could lead to 
wider arterioles, for example, through arteriole to venule shunting and local tissue hypoxia. 
Retinal arteriolar dilation is associated with progression of retinopathy 33 and presence of 
neuropathy 34. Retinal venular dilation is similarly associated with incidence and progression of 
retinopathy 35, incidence of nephropathy 36, prevalence and incidence of stroke 37,38 and 
progression of cerebral small vessel disease 39. Taken together with our findings, these results 
may explain why such complications are commonly present at diagnosis of type 2 diabetes or 
sometimes before. Retinal microvascular dilation seems to be reversible 40-42; however, 
whether this improvement in retinal microvascular dilation will translate into an improved 
prognosis with respect to complications of diabetes needs further investigation. 
Strengths of our study include the population-based design with oversampling of 
individuals with type 2 diabetes; the use of OGTT to characterize glucose metabolism status; 
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the extensive phenotyping, which enables detection of independent associations after 
extensive adjustments for potential confounders; and the broad array of additional analyses, 
which gave deeper insight into the associations. Our study also has limitations. First, the 
cross-sectional data cannot definitively establish a causal link between (pre)diabetes and 
retinal microvascular features. Nevertheless, there is extensive evidence that hyperglycemia 
causes microvascular dysfunction, and that the association may in fact be bidirectional 43,44. 
Second, our study population was 40-75 years of age, predominantly white, with relatively 
well-controlled blood glucose and cardiovascular risk factors, which should be taken into 
consideration when the findings are extrapolated to other populations. Third, although treating 
glucose metabolism status as a continuous variable increased statistical power to detect the 
associations of (pre)diabetes with retinal microvascular diameters and the results of likelihood 
ratio test confirmed the feasibility of this approach, it may also introduce bias into the estimates 
of associations, which are largely influenced by the difference in retinal microvascular 
diameters between the two extreme groups, i.e., the NGM and type 2 diabetes groups. Fourth, 
our fully adjusted model may have been over-adjusted, as a result of the inclusion of waist 
circumference, since for retinal venular diameters, and therefore the association of 
(pre)diabetes with retinal microvascular diameters may have been underestimated. Fifth, 
although investigational procedures were standardized, participants were allowed a light meal, 
which will increase variation in retinal microvascular diameters and thus bias associations 
towards the null. Sixth, although we adjusted for major potential confounders, there is still a 
possibility of residual confounding by variables that were not included in the analyses. 
In summary, this study has demonstrated that type 2 diabetes, higher levels of HbA1c, 
and, possibly, prediabetes are associated with wider retinal arterioles, independent of major 
cardiovascular risk factors, in a predominantly white population. These results support the 
‘ticking clock’ hypothesis, which postulates that microvascular dysfunction precedes the 
clinical diagnosis of type 2 diabetes 43,44, and may partly explain the occurrence of 
complications related to microvascular dysfunction in prediabetes and in early type 2 diabetes. 
Thus, microvascular dysfunction can be considered an early marker of (pre)diabetes and a 
potential target for intervention. 
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Supplemental Material to Chapter 3 
Additional analyses 
Associations remained similar when we replaced office systolic pressure with 24-hour 
ambulatory systolic blood pressure (available in 2545 individuals; Supplemental Table S3.2), 
or further specified blood pressure-lowering medication into renin-angiotensin-aldosterone 
system (RAAS) inhibitors and other types of antihypertensives (available in 2876 individuals; 
Supplemental Table S3.2) in the regression models. Associations also remained similar when 
we replaced waist circumference with BMI (available in 2875 individuals; Supplemental Table 
S3.3). 
    Associations again remained similar after additional adjustment for presence of 
retinopathy, presence of neuropathy, eGFR and albumin excretion, or history of cardiovascular 
disease (available in 2328 individuals; Supplemental Table S3.4). The associations also 
remained when physical activity and alcohol intake (available in 2535 individuals, 
Supplemental Table S3.5) were added to the models. Additional adjustment for plasma 
markers of inflammation (high-sensitivity C-reactive protein, serum amyloid A, interleukin-6, 
interleukin-8, and tumor necrosis factor-α) and their standardized sum score did not materially 
change the associations (available in 2848 individuals; Supplemental Table S3.6).  
Associations also remained similar when we excluded participants with outliers (defined 
as <3SD or >3SD) in retinal microvascular diameters (n=18; Supplemental Table S3.7), 
excluded participants with retinopathy (n=36; Supplemental Table S3.7), excluded participants 
with catch-up fundus photography (n=176; Supplemental Table S3.7), or excluded non-white 
population (n=41; Supplemental Table S3.7). Finally, we did not find any significant 
interactions with sex (p for interaction>0.440) or left versus right eye (p for interaction>0.579) 
with regard to the associations between glucose metabolism variables on the one hand and 
retinal outcomes on the other. 
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Supplemental Table S3.1 General characteristics of the study population and individuals excluded from 
the analyses due to missing values 
Characteristic 
Study population 
(N=2876) 
Missing Excluded due to missing 
values 
(N=534) 
p-value 
Age (years) 59.8±8.2 0 59.9±8.6 0.736 
Women (n,%) 1404 (48.8) 0 250 (46.8) 0.397 
Glucose metabolism status (n,%)  0  0.624 
- Normal glucose metabolism 1630 (56.7) 0 294 (55.1)  
- Prediabetes 433 (15.1) 0 78 (14.6)  
- Type 2 diabetes 813 (28.3) 0 162 (30.3)  
Diabetes duration (years) a 5.0 [1.0-11.0] 177 5.0 [1.5-11.0] 0.601 
Body mass index (kg/m2) 27.1±4.5 3 27.4±4.8 0.166 
Waist circumference (cm)  4   
- Men 101.5±12.1 2 102.2±12.5 0.340 
- Women 89.9±12.9 2 91.0±13.5 0.234 
History of cardiovascular disease (n,%) 473 (16.6) 65 88 (18.0) 0.431 
Office SBP (mmHg) 134.8±18.0 2 136.1±19.2 0.174 
Office DBP (mmHg) 76.2±9.8 2 76.0±9.8 0.678 
Ambulatory 24-hour SBP (mmHg) b 119.2±11.5 416 119.6 ±13.1 0.507 
Ambulatory 24-hour DBP (mmHg) b 73.9±7.2 416 74.1±7.1 0.561 
Hypertension (n,%) 1613 (56.1) 6 302 (56.9) 0.775 
Physical activity (hours/week) c 5.5±4.3 432 5.8± 4.7 0.136 
Smoking (%never/former/current) 35.1/52.0/12.9 49 31.5/49.9/18.6 0.003 
Alcohol intake (%none/low/high) 18.6/56.2/25.2 47 19.4/51.3/29.2 0.099 
Fasting glucose (mmol/L)  6.1±1.6 1 6.1±1.8 0.285 
2-hour postload glucose (mmol/L) d 7.9±4.3 251 7.7±4.0 0.168 
HbA1c (mmol/mol) 40.8±9.8 13 42.5±10.8 <0.001 
HbA1c (%)  5.9±0.9 13 6.0±1.0 <0.001 
Triglycerides (mmol/L)  1.4± 0.8 4 1.5±0.9 0.243 
Total-to-HDL cholesterol ratio 3.6±1.2 4 4.0±1.2 <0.001 
Total cholesterol (mmol/L) 5.2±1.2 4 5.2+1.2 0.701 
HDL cholesterol (mmol/L) 1.5±0.5 4 1.4+0.4 <0.001 
LDL cholesterol (mmol/L) 3.1±1.0 4 3.2±1.0 0.026 
Antihypertensive medication use (n,%) 1161 (40.4) 0 208 (39.0) 0.564 
Lipid-modifying medication use (n,%) 1033 (35.9) 0 198 (37.1) 0.624 
Diabetes medication use (n,%) 641 (22.3) 0 125 (23.4) 0.573 
-Insulin 167 (5.8) 0 49 (9.2) 0.005 
-Oral medication only 600 (20.9) 0 114 (21.3) 0.817 
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Supplemental Table S3.1 continued 
Characteristic 
Study population 
(N=2876) 
Missing Excluded due to missing values 
(N=534) 
p-value 
eGFR (ml/min/1.73m2)  88.2±14.7 33 87.5±15.9 0.314 
Albuminuria (n,%) e  243 (8.5) 42 48 (9.4) 0.732 
Retinopathy (n,%)  36 (1.3) 587 4 (3.0) 0.114 
Neuropathy (n,%) f 277 (10.9) 470 49 (12.2) 0.441 
CRAE (MU)  142.3±20.4 486 136.4±21.5 0.045 
CRVE (MU) 214.7±31.3 486 214.0±33.3 0.875 
Data are reported as mean ± SD or number (percentages %) as appropriate, except diabetes duration, which is 
reported as median [interquartile range]. Student’s t and chi-square tests were used to compare continuous and 
categorical variables between the study population and individuals excluded due to missing values, respectively. 
The Mann-Whitney test was used to compare diabetes duration between the two populations 
CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; DBP, diastolic blood 
pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, 
low density lipoprotein; MU: Measurement unit; SBP, systolic blood pressure      
a Available in 673 in the study population and 125 in the excluded group  
b Available in 2545 in the study population and 449 in the excluded group  
c Available in 2535 in the study population and 443 in the excluded group 
d Available in 2685 in the study population and 474 in the excluded group 
e Albuminuria was defined as a urinary albumin excretion of > 30 mg per 24 hours 
f Neuropathy was defined as a vibration perception threshold >25 V, and data were available in 2539 in the study 
population and 401 in the excluded group 
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Supplemental Table S3.2 Multivariable-adjusted difference in retinal vascular diameters in individuals 
with prediabetes and type 2 diabetes versus normal glucose metabolism (NGM) with replacement of 
office by 24-hour systolic ambulatory blood pressure in regression models 
Characteristic 
Prediabetes a 
B (95%CI) 
Type 2 diabetes a 
B (95%CI) 
p for trend 
CRAE (MU)    
   Model 1 0.02 (-2.29, 2.32) 1.67 (-0.21, 3.55) 0.096 
   Model 2a 0.12 (-2.24, 2.48) 2.27 (-0.05, 4.58) 0.069 
   Model 2b 0.03 (-2.33, 2.38) 2.09 (-0.22, 4.39) 0.094 
CRVE (MU)    
   Model 1 3.47 (-0.12, 7.05) 4.43 (1.50, 7.36) 0.002 
   Model 2a 2.03 (-1.65, 5.71) 2.93 (-0.67, 6.53) 0.099 
   Model 2b 1.98 (-1.69, 5.66) 2.83 (-0.76, 6.43) 0.110 
Regression coefficients (B) indicate the mean difference (95%CI) in retinal microvascular diameters with normal 
glucose metabolism as reference 
CI, confidence interval; CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; MU: 
Measurement unit 
a 24-h systolic ambulatory blood pressure was available in n=2545 of the study population (375 individuals with 
prediabetes and 722 individuals with type 2 diabetes) 
Model 1: adjustment for age and sex 
Model 2a: Model 1+adjustment for waist circumference, triglyceride levels, total-to-high-density-lipoprotein ratio, 
smoking status, office systolic blood pressure, use of antihypertensive medication and/or lipid-modifying 
medication 
Model 2b: Model 1+adjustment for waist circumference, triglyceride levels, total-to-high-density-lipoprotein ratio, 
smoking status, 24-hour systolic ambulatory blood pressure, use of antihypertensive medication and/or 
lipid-modifying medication 
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Supplemental Table S3.3 Multivariable-adjusted difference in retinal vascular diameters in individuals 
with prediabetes and type 2 diabetes versus normal glucose metabolism (NGM) with adjustment for 
renin-angiotensin-aldosterone system (RAAS)-inhibiting antihypertensives a and other types of 
antihypertensives or replacement of waist circumference by BMI in regression models 
Characteristic 
Prediabetes 
B (95%CI) 
Type 2 diabetes 
B (95%CI) 
p for trend 
CRAE (MU)    
   Model 1 0.42 (-1.73, 2.57) 2.29 (0.52, 4.06) 0.013 
   Model 2a 0.62 (-1.58, 2.83) 2.89 (0.69, 5.08) 0.013 
   Model 2b 0.60 (-1.60, 2.80) 2.83 (0.64, 5.03) 0.014 
   Model 2c 0.64 (-1.57, 2.84) 2.86 (0.67, 5.06) 0.013 
   Model 2d 0.53 (-1.67, 2.73) 2.69 (0.52, 4.87) 0.019 
CRVE (MU)    
   Model 1 3.84 (0.50, 7.18) 4.68 (1.93, 7.43) 0.001 
   Model 2a 2.40 (-1.03, 5.84) 2.87 (-0.55, 6.29) 0.083 
   Model 2b 2.37 (-1.06, 5.80) 2.89 (-0.53, 6.31) 0.081 
   Model 2c 2.38 (-1.06, 5.82) 2.90 (-0.53, 6.32) 0.080 
   Model 2d 2.39 (-1.04, 5.82) 2.87 (-0.52, 6.25) 0.080 
Regression coefficients (B) indicate the mean difference (95%CI) in retinal microvascular diameters with normal 
glucose metabolism as reference 
CI, confidence interval; CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; MU: 
Measurement unit 
a RAAS-inhibiting antihypertensives included angiotensin-converting-enzyme inhibitors, angiotensin receptor 
blockers, and renin blockers 
Model 1: adjustment for age and sex 
Model 2a: Model 1+adjustment for waist circumference, triglyceride levels, total-to-high-density-lipoprotein ratio, 
smoking status, office systolic blood pressure, use of antihypertensive medication and/or lipid-modifying 
medication 
Model 2b: Model 1+adjustment for waist circumference, triglyceride levels, total-to-high-density-lipoprotein ratio, 
smoking status, office systolic blood pressure, use of RAAS-inhibiting antihypertensives, and use of 
lipid-modifying medication 
Model 2c: Model 1+adjustment for waist circumference, triglyceride levels, total-to-high-density-lipoprotein ratio, 
smoking status, office systolic blood pressure, use of RAAS-inhibiting antihypertensives, use of 
non-RAAS-inhibiting antihypertensives and use of lipid-modifying medication 
Model 2d: Model 1+adjustment for BMI, triglyceride levels, total-to-high-density-lipoprotein ratio, smoking status, 
office systolic blood pressure, use of antihypertensive medication and/or lipid-modifying medication 
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Supplemental Table S3.4 Multivariable-adjusted difference in retinal vascular diameters in individuals 
with prediabetes and type 2 diabetes versus normal glucose metabolism (NGM) with additional 
adjustment for presence of retinopathy, presence of neuropathy, estimated glomerular filtration rate 
(eGFR) and albumin excretion, and history of cardiovascular disease 
Characteristic 
Prediabetes a 
B (95%CI) 
Type 2 diabetes a 
B (95%CI) 
p for trend 
CRAE (MU)    
   Model 1 1.85 (-0.52, 4.23) 1.92 (-0.002, 3.84) 0.040 
   Model 2a 2.16 (-0.26, 4.59) 2.40 (0.05, 4.76) 0.034 
   Model 2b 2.17 (-0.26, 4.59) 2.37 (0.001, 4.74) 0.036 
   Model 2c 2.16 (-0.26, 4.59) 2.31 (-0.07, 4.69) 0.042 
   Model 2d 2.41 (-0.01, 4.82) 2.51 (0.14, 4.89) 0.026 
   Model 2e 2.51 (0.09, 4.93) 2.54 (0.16, 4.92) 0.024 
CRVE (MU)    
   Model 1 4.41 (0.70, 8.13) 4.80 (1.80, 7.81) 0.001 
   Model 2a 3.31 (-0.49, 7.11) 3.10 (-0.60, 6.80) 0.075 
   Model 2b 3.33 (-0.47, 7.13) 2.89 (-0.83, 6.61) 0.094 
   Model 2c 3.33 (-0.48, 7.13) 2.88 (-0.86, 6.61) 0.096 
   Model 2d 3.75 (-0.05, 7.54) 3.17 (-0.55, 6.90) 0.065 
   Model 2e 3.89 (0.09, 7.69) 3.21 (-0.52, 6.94) 0.061 
Regression coefficients (B) indicate the mean difference (95%CI) in retinal microvascular diameters with normal 
glucose metabolism as reference 
CI, confidence interval; CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; MU: 
Measurement unit 
a Data were available in n=2328 of the study population (344 individuals with prediabetes and 683 individuals with 
type 2 diabetes) 
Model 1: adjustment for age and sex 
Model 2a: Model 1+adjustment for waist circumference, triglyceride levels, total-to-high-density-lipoprotein ratio, 
smoking status, office systolic blood pressure, use of antihypertensive medication and/or lipid-modifying 
medication 
Model 2b: Model 2a+adjustment for retinopathy 
Model 2c: Model 2b+adjustment for neuropathy (vibration perception thresholds >25 V) 
Model 2d: Model 2c+adjustment for eGFR and albumin excretion 
Model 2e: Model 2d+adjustment for history of cardiovascular disease 
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Supplemental Table S3.5 Multivariable-adjusted difference in retinal vascular diameters in individuals 
with prediabetes and type 2 diabetes versus normal glucose metabolism (NGM) with additional 
adjustment for physical activity and alcohol intake 
Characteristic 
Prediabetes a 
B (95%CI) 
Type 2 diabetes a 
B (95%CI) 
p for trend 
CRAE (MU)    
   Model 1 0.46 (-1.78, 2.70) 1.92 (0.05, 3.79) 0.049 
   Model 2a 0.72 (-1.58, 3.02) 2.63 (0.32, 4.95) 0.030 
   Model 2b 0.71 (-1.59, 3.01) 2.62 (0.30, 4.94) 0.031 
   Model 2c 0.66 (-1.63, 2.96) 2.17 (-0.18, 4.52) 0.076 
CRVE (MU)    
   Model 1 3.94 (0.43, 7.45) 3.39 (0.46, 6.33) 0.014 
   Model 2a 2.53 (-1.08, 6.15) 1.98 (-1.67, 5.63) 0.226 
   Model 2b 2.53 (-1.09, 6.15) 1.99 (-1.67, 5.64) 0.227 
   Model 2c 2.50 (-1.12, 6.12) 1.68 (-2.01, 5.38) 0.293 
Regression coefficients (B) indicate the mean difference (95%CI) in retinal microvascular diameters with normal 
glucose metabolism as reference 
CI, confidence interval; CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; MU, 
Measurement unit 
a Data were available in n=2535 of the study population (387 individuals with prediabetes and 685 individuals with 
type 2 diabetes) 
Model 1: adjustment for age and sex 
Model 2a: Model 1+adjustment for waist circumference, triglyceride levels, total-to-high-density-lipoprotein ratio, 
smoking status, office systolic blood pressure, use of antihypertensive medication and/or lipid-modifying 
medication 
Model 2b: Model 2a+adjustment for physical activity 
Model 2c: Model 2b+adjustment for alcohol intake 
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Supplemental Table S3.6 Multivariable-adjusted difference in retinal vascular diameters in individuals 
with prediabetes and type 2 diabetes versus normal glucose metabolism (NGM) with additional 
adjustment for inflammation 
Characteristic 
Prediabetes a 
B (95%CI) 
Type 2 diabetes a 
B (95%CI) 
p for trend 
CRAE (MU)    
   Model 1 0.32 (-1.83, 2.48) 2.29 (0.51, 4.07) 0.014 
   Model 2a 0.55 (-1.66, 2.76) 2.88 (0.68, 5.09) 0.013 
   Model 2b 0.54 (-1.67, 2.76) 2.87 (0.67, 5.08) 0.014 
CRVE (MU)    
   Model 1 3.53 (0.19, 6.87) 4.77 (2.01, 7.52) <0.001 
   Model 2a 2.17 (-1.27, 5.61) 3.01 (-0.42, 6.44) 0.074 
   Model 2b 2.06 (-1.38, 5.50) 2.87 (-0.57, 6.31) 0.089 
Regression coefficients (B) indicate the mean difference (95%CI) in retinal microvascular diameters with normal 
glucose metabolism as reference 
CI, confidence interval; CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; MU, 
Measurement unit 
a Inflammation was available in n=2848 of the study population (430 individuals with prediabetes and 803 
individuals with type 2 diabetes) 
Model 1: adjustment for age and sex 
Model 2a: Model 1+adjustment for waist circumference, triglyceride levels, total-to-high-density-lipoprotein ratio, 
smoking status, office systolic blood pressure, use of antihypertensive medication and/or lipid-modifying 
medication 
Model 2b: Model 2+adjustment for sum score of inflammation 
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Supplemental Table S3.7 Multivariable-adjusted difference in retinal vascular diameters in individuals 
with prediabetes and type 2 diabetes versus normal glucose metabolism (NGM) excluding outliers in 
retinal microvascular diameters, participants with retinopathy, participants with catch-up fundus 
photography, or non-white population 
Characteristic 
Prediabetes 
B (95%CI) 
Type 2 diabetes 
B (95%CI) 
p for trend 
Excluding outliers (defined as <3SD or >3SD) in retinal microvascular diameters (n=18) 
CRAE (MU)    
   Model 1 0.74 (-1.37, 2.84) 2.50 (0.77, 4.24) 0.005 
   Model 2 0.87 (-1.29, 3.03) 3.00 (0.84, 5.15) 0.008 
CRVE (MU)    
   Model 1 3.89 (0.60, 7.18) 4.99 (2.28, 7.71) <0.001 
   Model 2 2.47 (-0.91, 5.86) 3.28 (-0.09, 6.66) 0.046 
Excluding participants with retinopathy (n=36)  
CRAE (MU)    
   Model 1 0.41 (-1.75, 2.56) 2.27 (0.47, 4.06) 0.016 
   Model 2 0.59 (-1.62, 2.80) 2.80 (0.58, 5.02) 0.017 
CRVE (MU)    
   Model 1 3.77 (0.42, 7.11) 4.43 (1.65, 7.22) 0.001 
   Model 2 2.28 (-1.16, 5.72) 2.53 (-0.93, 5.98) 0.125 
Excluding participants with catch-up fundus photography (n=176)  
CRAE (MU)    
   Model 1 0.56 (-1.65, 2.77) 2.41 (0.61, 4.22) 0.010 
   Model 2 0.78 (-1.49, 3.04) 3.04 (0.81, 5.27) 0.009 
CRVE (MU)    
   Model 1 3.67 (0.22, 7.13) 4.80 (1.98, 7.62) 0.001 
   Model 2 2.26 (-1.29, 5.82) 2.99 (-0.52, 6.49) 0.082 
Excluding non-white population (n=41)  
CRAE (MU)    
   Model 1 0.43 (-1.73, 2.59) 2.24 (0.45, 4.03) 0.017 
   Model 2 0.65 (-1.57, 2.86) 2.91 (0.69, 5.13) 0.013 
CRVE (MU)    
   Model 1 3.74 (0.39, 7.10) 4.32 (1.54, 7.10) 0.001 
   Model 2 2.39 (-1.06, 5.84) 2.62 (-0.84, 6.08) 0.112 
Regression coefficients (B) indicate the mean difference (95%CI) in retinal microvascular diameters with normal 
glucose metabolism as reference 
CI, confidence interval; CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; MU, 
Measurement unit 
Model 1: adjustment for age and sex 
Model 2: additional adjustment for waist circumference, triglyceride levels, total-to-high-density-lipoprotein ratio, 
smoking status, office systolic blood pressure, use of antihypertensive medication and/or lipid-modifying 
medication 
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Supplemental Table S3.8 Multivariable-adjusted association between duration of type 2 diabetes and 
retinal microvascular diameters 
Characteristic 
Duration of type 2 diabetes a 
p for trend 2nd tertile 
B (95%CI) 
3rd tertile 
B (95%CI) 
CRAE (MU)    
   Model 1 -1.59 (-5.11, 1.93) 0.09 (-3.43, 3.61) 0.711 
   Model 2 -0.95 (-4.53, 2.62) 1.43 (-2.20, 5.06) 0.315 
CRVE (MU)    
   Model 1 -3.60 (-9.08, 1.88) -4.01 (-9.50, 1.47) 0.441 
   Model 2 -2.48 (-7.99, 3.02) -2.09 (-7.69, 3.51) 0.868 
Regression coefficients (B) indicate the mean difference (95%CI) in retinal microvascular diameters with the 
lowest tertile as reference 
CI, confidence interval; CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; MU, 
Measurement unit 
a Data were available in 673 individuals 
Model 1: adjustment for age and sex 
Model 2: Model 1+adjustment for waist circumference, triglyceride levels, total-to-high-density-lipoprotein ratio, 
smoking status, office systolic blood pressure, use of antihypertensive medication and/or lipid-modifying 
medication 
 
 
Supplemental Figure S3.1 Study population selection  
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Supplemental Figure S3.2 Age- and sex-adjusted association between retinal arteriolar diameters and 
retinal venular diameters. CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; 
MU, measurement unit 
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Summary 
In Chapter 1, we have described the worldwide epidemic of cardiometabolic diseases, which 
leads to lower quality of life, additional healthcare expenditure, and risk of early death 1,2. 
Investigations on the etiology can provide evidence for effective prevention and treatment. 
Microvascular dysfunction and physical (in)activity may play an important role in the 
development of cardiometabolic diseases, which, however, has not been well elucidated. 
Therefore, we aimed to investigate the association among microvascular dysfunction, physical 
(in)activity, and cardiometabolic diseases in a population-based study, The Maastricht Study 3. 
In this dissertation, we applied advanced technologies which enabled more accurate and 
comprehensive assessments of microvascular function and physical behavior. The description 
of measurement protocols is necessary for researchers to identify whether differences in results 
across studies are based on differences in methodologies, especially for the measurements 
that are yet to be standardized. In Chapter 2, we described the protocols of the microvascular 
measurements applied in The Maastricht Study, including non-invasive measurements in skin, 
retina, brain, and sublingual tissue as well as plasma and urine biomarker assessments. The 
use of these measurements enables the study of microvascular changes in various 
(patho)physiological conditions, as well as their similarity and difference across the territories. 
Following this, we summarized the main findings in The Maastricht Study involving these 
microvascular measurements up to 2018. These cross-sectional studies have demonstrated 
associations between multiple cardiovascular risk factors (age, sex, blood pressure, waist 
circumference, etc.) and diseases (e.g. (pre)diabetes and depression) and microvascular 
(dys)function 4-13. Finally, we provide a brief perspective of future microvascular investigations 
in The Maastricht Study, including fully automated analysis of microvascular imaging and 
longitudinal studies. We can already see some remarkable progress in the following chapters 
of this dissertation. 
In Chapter 3, we investigated whether (pre)diabetes and plasma glucose levels were 
associated with retinal microvascular diameters. We performed a cross‐sectional study in the 
framework of The Maastricht Study, including 2876 participants (n=1630 normal glucose 
metabolism, n=433 prediabetes, and n=813 type 2 diabetes). We used oral glucose tolerance 
test (OGTT) to define the glucose metabolism status. We took fundus photographs of each 
participant and used a semi-automated software (retinal health information and notification 
system [RHINO]) to determine retinal arteriolar and venular diameters. Multivariable regression 
analyses were performed and adjusted for age, sex, waist circumference, smoking status, 
systolic blood pressure, lipid profile, and the use of lipid-modifying and/or antihypertensive 
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medication. The results showed that type 2 diabetes, higher levels of hemoglobin A1c (HbA1c), 
and, possibly, prediabetes were significantly associated with wider retinal arteriolar diameters 
in a predominantly white population, independently of a broad array of potential confounders. 
The associations of (pre)diabetes and HbA1c with retinal venular diameters were directionally 
similar to those for arterioles, even though they were not statistically significant after adjustment 
for potential confounders. We additionally explored the association between retinal arteriolar 
and venular diameters, and found that retinal arteriolar diameters were associated with retinal 
venular diameters, independently of age, sex, height, body surface area, systolic blood 
pressure, and HbA1c level. Through more accurate assessments of the exposure and outcome, 
extensive adjustments for potential confounders, and the broad array of additional analyses, 
this study provided robust evidence and supported the concept that retinal microvascular 
changes already occur before the diagnosis of type 2 diabetes. 
In Chapter 4, we explored the association of generalized microvascular dysfunction with 
beta cell function in 2275 participant without history of diabetes in The Maastricht Study. We 
used 7-point OGTT to assess the fasting insulin secretion and glucose-stimulated insulin 
secretion. We assessed microvascular function by plasma biomarkers of endothelial function, 
urinary albumin excretion, retinal microvascular diameters, flicker light-induced retinal 
microvascular dilation, heat-induced skin hyperemia and calculated a composite score. The 
results showed that higher plasma biomarkers, higher urinary albumin excretion, and wider 
retinal microvascular diameters were significantly associated with higher insulin secretion in the 
fasting state. Higher levels of plasma endothelial biomarkers and urinary albumin excretion 
were associated with higher glucose-stimulated insulin secretion in the late phase. Notably, 
these associations are independent of insulin sensitivity and other potential confounders. Our 
study is the first population-based study to show a close relationship between microvascular 
dysfunction and beta cell function in humans in vivo. The findings support the hypothesis that 
islet microvascular dysfunction may contribute to altered insulin secretion. In contrast, most of 
previous animal and in vitro studies have shown an attenuated glucose-stimulated insulin 
secretion induced by islet microvascular dysfunction. We may attribute the inconsistency to 
species differences. In addition, most of our study population had normal glucose tolerance. 
In Chapter 5, we investigated whether systemic microvascular dysfunction was associated 
with incident cardiovascular disease, and if so, whether the associations differ across different 
vascular beds. Among 2531 participants in The Maastricht Study, we assessed microvascular 
function in multiple territories, including brain, retina, skin, plasma and kidney. A composite 
score of microvascular dysfunction was calculated. The follow-up of cardiovascular disease 
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was performed by use of an annual questionnaire. After a median follow-up of 5 years, we 
found that a higher composite score was associated with a higher risk of incident cardiovascular 
disease in the fully adjusted Cox regression model. In addition, the associations were not 
significantly different with regard to outcomes in coronary, cerebral, and peripheral arteries. 
Based on these findings, systemic microvascular dysfunction may play an important role in the 
development of cardiovascular diseases in different vascular beds. 
In Chapter 6, we examined the association between the volume and the pattern of 
sedentary behavior and physical activity with incident cardiovascular disease. We included 
4706 participants without history of cardiovascular disease (n=336 had incident events) in The 
Maastricht Study. We used the activPAL3 activity monitor to assess physical variables, 
including sedentary time, light-intensity physical activity (LIPA), moderate-to-vigorous-intensity 
physical activity (MVPA), vigorous-intensity physical activity (VPA), number of sedentary breaks, 
number of prolonged sedentary bouts (≥30 minutes), average sedentary bout duration, and 
physical activity pattern. We performed a follow-up of cardiovascular disease using an annual 
questionnaire (median follow-up=5.1 years). The results showed a significant sex difference in 
the association of volume of sedentary behavior and physical activity with incident 
cardiovascular disease. In women, more MVPA was associated with an increased risk of 
developing cardiovascular disease. The association was not independent of mobility limitation 
and body mass index (BMI). In men, more LIPA was associated with a higher risk of 
cardiovascular disease, independently of potential confounders and mediators. This study is 
the first prospective study including middle to older aged population to investigate the 
association of accelerometer-measured sedentary behavior and physical activity with incident 
cardiovascular disease and show the shape of dose-response relations in sex subgroups. The 
linear association of MVPA with incident cardiovascular disease in women supports the advice 
on MVPA in the current guidelines, though meeting guidelines of >150 minutes/week of MVPA 
was not significantly associated with incident cardiovascular disease. In addition, the 
association of LIPA with incident cardiovascular disease in men may suggest a potential role 
of occupational physical activity in the development of cardiovascular disease. 
Methodological considerations 
Internal validity 
This dissertation was aimed to enhance our knowledge on the role of microvascular dysfunction 
and physical activity in cardiometabolic diseases. However, the results could deviate from the 
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truth due to methodological limitations (systemic error). Therefore, we should cautiously 
consider the limitations and their influence when interpreting our findings. 
Selection bias 
Selection bias occurs when the sample is not representative of the source population. Among 
a variety of selection bias, sampling bias and attrition bias may be involved in this dissertation. 
On one hand, The Maastricht Study is oversampled with type 2 diabetes 3, which was designed 
to increase statistical power to detect the difference between individuals with and without 
diabetes (Chapter 3). However, the association of microvascular dysfunction with incident 
cardiovascular disease did not differ with diabetes status (Chapter 5), indicating that the results 
may not be biased due to the oversampling. On the other, the participants were recruited 
through mass media campaigns and from the municipal registries and the regional Diabetes 
Patient Registry by mailings, suggesting that a majority of participants with diabetes in The 
Maastricht Study were well treated. In addition, participation in The Maastricht Study required 
three and a half days for multiple measurements. Therefore, individuals with a relatively healthy 
condition and higher educational level were more likely to participate, and led to underestimated 
associations and limited external validity.  
    The complete-case analysis approach in our studies can cause attrition bias 14. We 
excluded participants with missing data on exposures (microvascular dysfunction and physical 
behavior), outcomes (beta cell function and incident cardiovascular disease), and/or covariates. 
First, most of the missings on microvascular measures were of logistics reasons. As the 
microvascular measurements were implemented gradually in The Maastricht Study, it is 
conceivable that only participants recruited after the implementation underwent the 
measurements (Chapter 2). In this dissertation, individuals with and without data on retinal 
microvascular diameters (n=486) and confounders (n=48) had a highly comparable 
cardiometabolic profile (Chapter 3). In addition, for those who had not the measurement, we 
attempted to perform catch-up fundus photography.  Previous investigations also showed that 
excluding individuals without data on flicker light-induced retinal microvascular dilation, heat-
induced skin hyperemia and/or physical activity may not affect the results 7,15. However, it was 
reported that participants without measurement of cerebral small vessel disease had a worse 
cardiometabolic profile 8. Therefore the association may be distorted in our study including the 
brain marker as measure of microvascular dysfunction (Chapter 5). Second, we excluded 249 
participants due to missing data on beta cell function (Chapter 4). As these data were 
unavailable mostly in participants with diabetes, who were already excluded by intention, we 
assumed it unlikely to influence the results. Third, in the longitudinal studies (Chapter 5, 6), ~5% 
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of the participants did not have any follow-up data on incident cardiovascular disease. The loss 
to follow-up can result from adverse cardiovascular conditions. However, incident events within 
the first year of follow-up may suggest a reverse association. We therefore considered a limited 
influence on our results. 
Information bias 
Measurement errors occur in a differential or nondifferential manner to all study subjects. These 
errors may cause bias in the estimation of associations, i.e., information bias 16. The differential 
errors can lead to both overestimation and underestimation of the true association. 
Nondifferential errors, especially that of an exposure variable, can also bias the estimates of 
assassinations to null 17. 
In investigating the association between (pre)diabetes and retinal microvascular diameters 
(Chapter 3), we used OGTT to define glucose metabolism status. Compared with fasting 
plasma glucose, random plasma glucose and HbA1c, OGTT is more sensitive to an impaired 
glucose metabolism, more pathophysiologically indicative, and is the gold standard for 
diagnosis of diabetes 18. Considering its relatively poor day-to-day reproducibility which may 
cause undifferential error and underestimation of associations, we also used measures of 
glycemia to confirm the association, and the results were consistent.  
In the studies of microvascular dysfunction as an exposure (Chapter 4, 5) or outcome 
(Chapter 3), the measurements were performed by well-trained researchers (Chapter 2). We 
had specific requirements regarding effects of smoking, diet, exercise, and room temperature 
on microvascular function 3,19,20. What’s more, we used multiple measurements and a 
composite score of microvascular dysfunction, considering the biological variability and 
heterogeneity across different microvascular beds (Chapter 5). Also because of the 
heterogeneity 21, we should take caution when inferring the results in other territories to islet 
microvasculature (Chapter 4). In the measurement of retinal microvascular diameters (Chapter 
3), we applied a semi-automated analysis, which is more reproducible than manual procedure 
22. As the fundus photograph of only one eye was analyzed (randomly chosen), differences 
between left and right eye may exist. However, we did not find significant difference in the 
association. In addition, we used a revised Knudtson-Parr-Hubbard formula 23, and therefore 
the observed diameters were not influenced by number of microvessels in the calculation. 
Assuming that there were more errors in measuring retinal microvascular diameters in 
participants with retinopathy, we excluded these patients in the sensitivity analysis and found 
similar results. Nevertheless, the reproducibility was not perfect and we did not apply repeated 
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measurements. This may cause bias that resulted in nonsignificant and underestimated 
associations. 
Similar to the microvascular measurements, there is no consensus regarding which indices 
reflect the beta cell function best. The physiological mechanism underlying insulin secretion 
was different between fasting and glucose-stimulated states, as well as the early and late phase 
after the glucose stimulation 24. We therefore measured beta cell function by fasting insulin 
secretion and glucose-stimulated insulin secretion in the early and late phase (Chapter 4). The 
use of these indices may provide a more comprehensive understanding of physiological insulin 
secretory response to glucose ingestion and microvascular alternation. Considering the effects 
of glucose levels and insulin clearance on insulin concentration in the circulation, we measured 
C-peptide instead of insulin levels and adjusted for glucose levels. The results based on these 
simple indices were relatively easy for understanding and comparing with results of animal 
experiments. However, use of these indices can also cause information bias. For example, we 
measured C-peptide and glucose levels in the circulation, and therefore the indices may not 
reflect the true beta cell function. 
In Chapter 6, we used activPAL3 activity monitor to measure daily physical activity and 
sedentary behavior, which was more accurate than self-reported questionnaires and hip-worn 
accelerometers 25-27. However, the accelerometer may underestimate the physical activity and 
cause misclassification, as it cannot well capture some activities, such as balance and 
resistance training 28. Regarding the awareness of wearing the device, which may influence the 
physical behavior, we excluded those with accelerometer data less than 4 valid days (n=211, 8 
consecutive days in total) and found that the results were similar. 
In the prospective studies (Chapter 5, 6), we used an annual self-reported questionnaire 
for follow-up of cardiovascular disease. We did not include cardiovascular death in the outcome. 
As cardiovascular disease is a major cause of death in the general population 29, the association 
may be underestimated. In addition, use of self-reported questionnaire may cause 
misclassification due to misunderstanding of the questions and reporting bias 30,31. We validated 
the self-reported cardiovascular diseases with medical records in The Maastricht Study 
(Chapter 5). The sensitivity and specificity were 0.80 and 0.89 respectively. However, 52% of 
self-reported cardiovascular diseases were not recorded in the medical data, most of which 
were reported as peripheral vascular disease. Although this inconsistency may be due to 
misunderstanding, there was a possibility that the participants went to other hospital for 
diagnosis and treatment. Additionally, a reporting lag may exist between the onset of symptoms 
and diagnosis, as well as between the diagnosis by general practitioner and recording on file. 
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This is supported by the finding in other cohort that self-reported peripheral vascular disease 
was associated with future vascular events (myocardial infarction, ischemic stroke, and 
vascular death) 32. 
Errors can also occur in the measurement of confounders, which increases the possibility 
of residual confounding (see confounding and overadjustment section).  
Confounding and overadjustment 
Extensive phenotyping in The Maastricht Study has enabled detection of independent 
associations after adjustment for potential confounders, i.e., a third variable that is associated 
with both exposure and outcome variables and thus affect their association 16. For example, 
glucose-lowering interventions, such as diet and metformin, can affect both microvascular 
function and beta cell function 33-35. To avoid this potential confounding, we excluded individuals 
with a history of diabetes (Chapter 4). Ignoring the potential confounding may increase the 
chance of type 1 error. The confounding effect can also be controlled in the multivariable 
regression analysis. However, residual confounding by inaccurate measurement of potential 
confounders can increase the chance of type 1 error. In particular, 24-hour ambulatory blood 
pressure is a more accurate measure of blood pressure 36, as it can eliminate the ‘white coat’ 
effect that occurs in measuring office blood pressure (Chapter 3,4,5). The Dutch Healthy Diet 
Index 2015 (Chapter 5,6) may be an accurate assessment of the diet quality of our study 
population, as it was based on the data of local inhabitants 37,38. In Chapter 4, we used the 
Matsuda index as a measure of insulin sensitivity. Despite its good correlation with the ‘gold 
standard’ hyperinsulinemic-euglycemic clamp in individuals without diabetes 39, the inaccurate 
assessment of insulin sensitivity may lead to residual confounding in the association of 
microvascular (dys)function and beta cell function. 
Overadjustment bias may have occurred in our fully-adjusted models 40. For example, 
weight gain (measured as BMI and waist circumference) can be on the causal pathway between 
microvascular dysfunction and type 2 diabetes (Chapter 3). Therefore, we conservatively 
interpreted the association of (pre)diabetes with retinal venular diameters, which was 
statistically nonsignificant. In Chapter 6, we constructed a separate model to adjust the 
association for mobility limitation and BMI, since both of them can be on the pathway between 
physical (in)activity and cardiovascular disease.  
External validity 
The findings in The Maastricht Study can be generalized to a population with similar 
characteristics, i.e., middle- to older-aged white population with well-controlled cardiometabolic 
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risk factors (Chapter 3, 5, 6). Additionally, our finding in the association of microvascular 
dysfunction with beta cell function was restricted to the population without treated diabetes 
(Chapter 4). Nevertheless, we found a similar association in the population of The Cohort on 
Diabetes and Atherosclerosis Maastricht (CODAM) Study. The participants of the CODAM had 
worse cardiometabolic profiles than the participants of The Maastricht Study. Besides, the 
observed associations in this dissertation were similar for the population without retinopathy 
(Chapter 3), for the population with normal glucose metabolism (Chapter 4), and for the 
population without a history of cardiovascular disease (Chapter 5). Therefore, the findings may 
be applicable to a broader population. Indeed, the associations of diabetes with retinal 
microvascular diameters have been found in other studies on non-Whites as well 41-47. In 
general, the primary goal of this dissertation was to provide robust evidence for a better 
understanding of the role of microvascular function and physical behavior in cardiometabolic 
diseases. The demonstration of valid results with minimum bias was in the highest priority. 
Temporality 
In Chapters 3 and 4, we used cross-sectional data of The Maastricht Study, which cannot build 
a solid causal link between the exposures and the outcomes in our hypotheses. For instance, 
we cannot determine whether microvascular dysfunction preceded greater insulin secretion, 
and evidence of previous experimental studies also favors the reverse relationship 48,49, i.e., 
hyperinsulinemia can impair microvascular function. Nevertheless, we at least show a 
possibility that the influence of microvascular dysfunction on beta cell function in humans may 
differ from that has been found in animal and in vitro studies. In addition, the bidirectional 
relationship may exist in both studies and construct a vicious circle (Chapter 3, 4). In Chapters 
5 and 6, we used longitudinal data and thus the reverse causality can be excluded 16,50. Note 
that in Chapter 6 we excluded the cardiovascular events that occurred within the first year of 
follow-up, which made the causal relationship more valid. As addressed previously, the 
observed associations in this dissertation were adjusted for a broad array of potential 
confounders, and the associations remained in most cases. Although we cannot exclude the 
possibility of residual confounding, these results strengthen our hypothesis that the 
associations were causal 50. 
 
Conclusion and future directions 
Taken together, the results in this dissertation show that both microvascular dysfunction and 
physical (in)activity may play an important role in cardiometabolic diseases (Figure 7.1). The 
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findings support the ‘ticking clock’ hypothesis 51 that the risk of cardiovascular disease already 
increases before the diagnosis of type 2 diabetes. More specifically, impaired glucose 
metabolism can lead to microvascular dysfunction. The effect can be systematic, as the 
association exists not only for the microvasculature in retina but also for that in skin and brain 
7,8. In addition, the association between microvascular dysfunction and (pre)diabetes can be 
bidirectional. In individuals without a history of diabetes, we found that generalized 
microvascular dysfunction is associated with greater insulin secretion. This finding, consistent 
with a hyperbola relationship between insulin sensitivity and beta cell function 52, may support 
the concept of beta-cell exhaustion that type 2 diabetes could be a consequence of insulin 
depletion, rather than beta cell dysfunction 53. We also found associations of microvascular 
dysfunction (in general population) and physical inactivity (in women) with higher risk of 
cardiovascular disease. According to a previous finding in The Maastricht Study 15, physical 
inactivity can be a determinant of microvascular dysfunction and associated with greater odds 
for metabolism syndrome and type 2 diabetes 54. Therefore, physical activity may reduce the 
risk of cardiometabolic diseases via protecting microvascular function. 
Further investigations are still needed. First, regarding the bias due to loss to follow-up, we 
need to include (cardiovascular) mortality in the outcome data. Second, we investigated the 
association between microvascular dysfunction and beta cell function only with cross-sectional 
data. Therefore, longitudinal studies are needed to strengthen the causality. In addition, a more 
accurate measurement of islet microvascular function needs to be developed. Third, there is a 
need for studies that investigate potential interventions to counter the effects of microvascular 
dysfunction on the adverse cardiometabolic outcomes. For instance, whether the physical 
activity-improved microvascular function can reduce the risk of cardiovascular disease remains 
unknown. Finally, some findings in this dissertation (e.g., the association of microvascular 
dysfunction with beta cell function) have not been validated with other populations. The 
associations are assumed to be qualitatively similar but in different degrees due to the different 
distribution of cardiometabolic risk factors across populations. The suggestions based on these 
studies may be more tailored to local conditions. 
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Figure 7.1 Associations of microvascular dysfunction and physical activity with cardiometabolic diseases. 
Solid arrows indicate associations found in the present dissertation. Black dashed lines represent potential reverse 
associations. Blue dashed lines represent associations in previous analyses from The Maastricht Study 
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Social and economic relevance 
Ideally, any theoretical and technological innovation in medical research can be applied to 
practice. However, Rome was not built in a day; it was built due to unremitting efforts of several 
generations. When M. Malpighi and A. van Leeuwenhoek first observed the blood flow through 
capillaries under the microscope, they might not have realized that a new chapter in the 
knowledge of circulation and its (patho)physiological functions embarked. Moreover, the finding 
has driven the industry which developed a variety of techniques to quantitatively assess 
microvascular function. This is also the case for assessments of physical behavior. As we 
described in the previous chapters, we have gained more knowledge by use of these 
assessments in the population-based cohort. Although this dissertation only investigates 
microvascular (dys)function and physical (in)activity as determinants of cardiometabolic 
diseases, further investigations may focus on their values of prevention and treatment based on 
our findings. If these assessments are proven to have higher values of prevention and 
treatment, they are expected to reduce premature death, disability, and medical expenses due 
to cardiometabolic diseases. 
  
Target group 
Our study population included middle- to older-aged population. Nevertheless, our findings may 
be generalized to a broader population, even to young adults. According to our results, better 
microvascular function and physical activity at baseline reduced participants’ risk of 
cardiovascular diseases at any given time. Previous meta-analyses have shown that 
microvascular dysfunction is associated with a higher risk of type 2 diabetes which may occur 
after 10 years 1,2. These results support a concept that the risk of cardiometabolic diseases may 
begin to increase at a younger age, and preventive awareness and measures should be taken 
earlier. 
 
Innovation 
The application of innovative technologies in this dissertation have enhanced the reliability of 
our findings and confirmed the feasibility of their use in a large population. The use of multiple 
microvascular measurements enabled us to assess microvascular function across vascular 
beds (i.e., arterioles, venules, and capillaries) and territories and their similarity and difference 
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in response to various (patho)physiological conditions. No previous studies have applied such 
systems physiology approach. Regarding the measurement of physical behaviors, we also 
included multiple parameters to investigate the effect of volume and pattern of physical 
behaviors on the risk of cardiovascular disease. In addition, we used thigh-worn 
accelerometers, which is more accurate than hip-worn accelerometers and self-reported 
physical activity questionnaires to assess physical activity. 
The extensive phenotyping in The Maastricht Study has allowed us to investigate 
independent associations adjusted for many potential confounders. Additionally, it allowed 
further exploration of underlying mechanisms. For instance, it has been proposed that 
diabetes-associated retinal venular dilation is related to inflammation 3,4. However, additional 
adjustment for inflammation did not change the association between (pre)diabetes and retinal 
venular diameters in our study (Chapter 3), suggesting that inflammation may not explain the 
retinal venular dilation. 
 
Implementation 
Microvascular measurements for screening 
If microvascular dysfunction can predict the risk of cardiometabolic diseases with high 
sensitivity, the measurements may be used for screening. Among the specific measurements, 
the fundus photography is common in hospitals and time-saving. The Atherosclerosis Risk in 
Communities (ARIC) Study reported that assessing retinal microvascular diameters in addition 
to the Pooled Cohort Equations would reclassify 21% of low-risk women as intermediate risk 5. 
However, determining cut-off values is necessary for screening but difficult. We and others 
have found that (pre)diabetes is associated with wider retinal arterioles (Chapter 3), whereas 
narrower retinal arterioles are associated with a higher risk of cardiovascular diseases. This 
may suggest different pathophysiological mechanisms as well as a bidirectional change in 
retinal arteriolar diameters with the progression of disease. In addition, we should take into 
account the strong confounding effects of age, sex, blood pressure and BMI (or waist 
circumference). 
Microvascular function as a target of treatment 
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Current evidence supports that microvascular dysfunction may play a role in cardiometabolic 
diseases (Chapter 3 and 5) 1,2,5. Therefore, interventions on microvascular function may be 
promising for the treatment. Some medications on the market have already shown efficacy in 
improving microvascular function. For instance, calcium dobesilate, a vasoprotective that 
reduces capillary permeability, can effectively alleviate diabetic retinopathy and nephropathy 6,7. 
Some traditional Chinese medicine, antihypertensive and antihyperglycemia agents, and 
lifestyle interventions can also improve microvascular function 8-10, but whether the 
improvement can retard the development of cardiometabolic diseases needs further 
investigation. Another important question is when the intervention should be implemented. As 
microvascular dysfunction can occur long before the diagnosis of diabetes and cardiovascular 
diseases, early intervention may be taken for prevention. Of note, clinicians need to assess 
other profiles of patients before and after applying the medication, as most of the current 
medications are non-specific to microvasculatures. 
Physical activity for prevention and treatment of cardiometabolic diseases 
Lifestyle interventions often serve as primary prevention strategies for cardiometabolic 
diseases, with the advantages of less expenses and side effects. A meta-analysis showed that 
diet and physical activity interventions for adults without known cardiometabolic risk factors 
benefit cardiovascular health in 6-12 months of follow-up with a dose-response relationship 11. 
In addition, adults at high risk may benefit more from these interventions 12. With regard to 
long-term benefits, a recent meta-analysis showed that more daily step counts are associated 
with a lower risk of all-cause mortality, and cardiovascular morbidity and mortality in adults 13. 
Another meta-analysis revealed that more self-reported sedentary behavior may increase the 
risk of all-cause and cardiovascular mortality and incident type 2 diabetes, independently of 
physical activity time 14. However, we found that accelerometer-measured sedentary time is not 
independently associated with incident non-fatal cardiovascular disease (Chapter 6). The 
results are similar in children and adolescents; more moderate-to-vigorous-intensity physical 
activity (MVPA) is associated with better cardiometabolic risk factors, whereas sedentary time 
is not associated with cardiometabolic risk factors independently of MVPA 15. In addition, 
physical activity can improve physical fitness and reduce disability in patients with stroke 16, and 
reduce all-cause hospital admissions and cardiovascular mortality in patients with coronary 
heart disease 17. 
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Taken together, physical activity can be an effective intervention for the prevention and 
treatment of cardiometabolic diseases, whereas the evidence showing the cardiometabolic 
benefits of decreased sedentary time remains insufficient. Advocacy via media and increasing 
public fitness equipment may facilitate physical activity of people. For individuals, the type and 
intensity of physical activity should be selected with consciousness of safety and long-term 
compliance. 
 
Conclusion 
In summary, identification of potential risk factors and treatments is expected to lower the 
burden of cardiometabolic diseases on the patients and society. This dissertation provides 
robust evidence which shows microvascular (dys)function and physical (in)activity as 
determinants of cardiometabolic diseases and promising targets for the prevention and 
treatment. However, further investigations are needed to evaluate the rationality and feasibility 
of their use in the clinical practice.   
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